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INTRODUCTION 
 
 Nosocomial infection (NI) is defined as an infection developing in 
hospitalized patients, which was neither present nor in incubation at the time of 
their admission. Infections are considered nosocomial if they first appear 48 
hours or more after hospital admission or within 10 days after hospital 
discharge.1,2   
 Nosocomial infections cause substantial morbidity and mortality, prolong 
the hospital stay of affected patients, and increase direct patient-care costs.3 NI is 
among the most difficult problems confronting clinicians who deal with severely ill 
patients. The incidence of these hospital-acquired infections varies with the size 
of hospitals, with specialties of wards, and with many other factors such as length 
of hospital stay, local trends in antibiotic usage, nursing and hygiene conditions, 
hospital design and geographical distribution of patients at risk.4 
 An average incidence of NI can be estimated at 5-10%, with higher rates 
in large university hospitals, and reaching up to 28% in the intensive care unit 
(ICU).4  The Study on the Efficacy of NI Control (SENIC) in 1975 in USA, found 
that NI develops in 5%-6% of hospitalized patients.5 Later in 1984, the National 
Nosocomial Infection Surveillance (NNIS) in USA, found an overall rate of 3.4 
infections per 100 patients discharged and suggested that the true incidence is 
underestimated.5 
  In general, it is expected that the incidence of NIs in dermatology patients 
will be low, but information on the occurrence of NIs in dermatology care is very 
limited. However, as these infections may lead to a prolonged hospital stay and 
severe complications, it is useful to provide dermatologists with more detailed 
data on the incidence on NIs in this setting.6 The incidence of sepsis in 
dermatology inpatients in a study in AIIMS, Delhi in India was reported to be 
6.6%.7 
 There is a paucity of data on the incidence of NI and of risk factors for 
acquiring NI among dermatology inpatients and this has prompted this study. 
 
AIMS AND OBJECTIVES 
 
1. To study the incidence of NI among a cohort of dermatology inpatients in a 
tertiary care centre. 
 
2.  To study the pathogens responsible for NI and their antibiotic susceptibility. 
 
3. To study the risk factors for NI in these patients. 
 
REVIEW OF LITERATURE 
 
Health care-associated infections constitute a major challenge of modern 
medicine and are considered one of the most accurate indicators of the quality of 
patient care.8  
The acquisition of nosocomial pathogens depends on a complex interplay 
of the host, pathogen, and environment. The important host factors found in the 
development of infection are the underlying medical disorder, immune function, 
nutrition, age, and genetic factors. Microbial factors include the minimum 
inoculating dose sufficient to cause infection, virulence, pathogenicity, infectivity, 
and ability to produce a latent infection. The environment serves as a reservoir 
where a pathogen maintains its presence and replicates. The reservoirs for 
Gram-positive bacteria are generally human hosts, whereas Gram-negative 
bacteria may have a human, an animal or an inanimate reservoir. The source is 
the place from which the infectious agent passes to the host by either direct or 
indirect contact.9  
NI may result from either endogenous flora, reactivation of latent infective 
agents or exogenous flora.9 NI can be characterized as sporadic, endemic or 
epidemic on the basis of past occurrence of that disease in relation to time, place 
and person. Most NI are endemic, are endogenous in origin and occur in 
predictable frequencies in a time period. In an epidemic NI there is a significant 
increase in incidence above the expected.10  Approximately 10% of 
hospitalized patients develop infections every year. The rate of developing 
nosocomial or hospital acquired infections in developing countries is as high as 
25%. It has been estimated that up to one third of these infections are 
preventable.2 The incidence of NI is highest in surgical wards and ICUs, and 
lowest in medical units.11  
Depending on the site of infection, NI can be classified as infections of the 
bloodstream, urinary tract, respiratory tract, gastrointestinal tract, burns, surgical 
site, intravenous catheter related and others.12  
NI typically affect patients who are immunocompromised because of age, 
underlying diseases, or medical or surgical treatments.13 Acute health care 
facilities serve both as a point of origin and as a reservoir for highly resistant 
pathogens. This is because the patients admitted to hospitals are subjected to 
intensive and prolonged antimicrobial use. In addition, failure in infection control 
practice can result in cross-infection and outbreak of NIs with highly resistant 
bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant enterococci (VRE) and multi-resistant Gram-negative 
bacilli(GNB) as well as resistant fungal infections. Some of these resistant strains 
have now spread outside hospitals causing infections in the community.2  
Nosocomial infection adds to functional disability and emotional stress of 
the patient and may, in some cases, lead to disabling conditions that reduce the 
quality of life. NI is also one of the leading causes of death.  Prolonged stay not 
only increases direct costs to patients or payers but also indirect costs due to lost 
work. The direct costs are due to increased use of drugs, the need for isolation, 
and the use of additional laboratory and other diagnostic studies. NI adds to the 
imbalance between resource allocation for primary and secondary health care by 
diverting scarce funds to the management of potentially preventable conditions.14  
Surveillance of NI is the foundation for organizing and maintaining an 
infection control programme. Different methods of surveillance exist: 
• Hospital-wide surveillance which provides data on all infection 
sites and units, establishes baseline rates, identifies risk factors 
and allows recognition of outbreaks.  
• Objective / priority based surveillance focuses on specific 
problems.  
• Targeted surveillance focuses on patients at risk.  
• Limited periodic surveillance decreases possibility of missing an 
outbreak and increases the efficiency of surveillance.2 
 
 
 
 
 
 
 
 
 
 
 
Historical milestones in NI is shown in table 1.15 
Table 1: HISTORICAL MILESTONES 
Name Relevance Year 
Semmelweiss Hand-washing practice 1861 
Florence Nightingale Principles of nursing, hospital design 
and hygiene 
1863 
Louis Pasteur Health hygiene 1873 
Lister Antiseptic theory 1874 
Gustao Neubar Introduced use of masks and gowns in 
surgery 
1883 
Halsted Introduced rubber gloves in surgery 1890 
Von Bergman Steam sterilization 1896 
 
PREVALENCE OF NOSOCOMIAL INFECTION 
 Nosocomial infection is an important focus of infection prevention in all 
countries, but in developing countries they are a major cause of preventable 
disease and death.14 A prevalence survey conducted under the auspices of the 
WHO in 55 hospitals of 14 countries representing 4 WHO regions (Europe, 
Eastern Mediterranean, South-East Asia and Western Pacific) showed that an 
average of 8.7% of hospital patients had NI. The highest frequencies of NI were 
reported from hospitals in the Eastern Mediterranean and South-East Asia 
regions, 11.8 and 10.0% respectively, with a prevalence of 7.7 and 9.0% 
respectively in the European and Western Pacific regions.  Nosocomial infection 
rates range from as low as 1% in a few countries in Europe and the Americas to 
more than 40% in parts of Asia, Latin America and sub-Saharan Africa.16 The 
studies on the prevalence of NI in developing countries is summarized in table 2.  
  
Table 2: Studies on prevalence of NI in developing countries in different 
settings 
No. Authors (year) Setting (%) NI 
1. Mehta et al (2007)17 ICU 4.4 
2. Cherian R et al (1999)18 ICU 50.8 
3. Inan et al (2005)19 ICU 16.6 
4.  Lakshmi KS et al (2006)20 PICU 30.17 
5. Khilnani et al (2004)21 PICU 16.86 
6. Effird MM et al (2005)22 Neonatal ICU 8.4 
7. Malik A et al (2001)23 Neonatal unit 26.9 
8. Zacharia A et al (1993)24 Medical ward+ICU 9.7 
9. Abdel-Fattah et al (2005)25 General ward 48.3 
10. Zhang et al (1991)26 Total hospital 13.1 
11. Wu AH et al (2003) 27 Total hospital 1.3 
 
Annual prevalence surveys are used to measure the burden of hospital acquired 
infections in many countries. The prevalence per 100 admissions was 9.1 in 
Greece in 1999, 8.0 in Denmark in 1999, 7.0 in Spain in 1997, 5.1 in Norway 
in2002 and 4.6 in Slovenia in 2001. In 1995 CDC estimated that 1.9 million 
hospital associated infections (HAIs) occurred in US hospitals, and in 2002 they 
estimated 1.7 million HAIs.28 The prevalence of NI in developed countries is 
shown in table 3. 
 
 
 
Table 3: Reported studies on prevalence of NI in developed countries in 
different settings 
 
 
Predisposing factors in NI 
Patient factors  
 Various patient factors predisposing to NI include debility, extremes of 
age, impaired gag reflex, immunosuppressive illness, immobility, dehydration and 
normal flora.11 
 
Surgical and Medical interventions 
 Various surgical interventions like incisions, intravascular devices, urinary 
catheterization, prosthetic joints and heart valves provide a protected niche for 
bacterial growth. Medical interventions such as antibiotic use, 
immunosuppression, anaesthesia and ventilation, total parenteral nutrition, use of 
histamine (H2) receptor blockers may potentiate acquisition of NI.11 
 
 
 
No. Authors (year) Setting % NI 
1. Vincent et al  (1995)29  ICU 20.6 
2. Pittet et al (1999)30 Total hospital 11.6 
3. Ortona et al (1985)31 Total hospital 6.75 
4. Lizioli et al (2003)32 Total hospital 4.9 
5. Kim et al (2000)33 General ward 3.7 
Hospital environment  
 Environmental factors such as lack of hygiene, overcrowding, 
understaffing, cross-infections, environmental organisms, hospital pathogens and 
duration of hospital stay are responsible for hospital acquired infections.11 
 In the European Prevalence of Infection in Intensive Care (EPIC) study by 
Vincent LJ et al29 in ICUs the following factors increased the odds of death: age 
older than 60 years, wound / blood stream infection, sepsis, pneumonia, urinary 
tract infection, organ failure, cancer, diabetes and total length of hospital stay. In 
a study by Dettenkofer M et al6 in a German university hospital most of the NIs 
were detected after surgery especially in patients with basal cell carcinoma 
(BCC), the incidence of surgical site infections (SSI) being 7.6%. Wahie S et al34 
in their study on wound complication rate for dermatology inpatients undergoing 
diagnostic skin biopsies found wound complications in 29 biopsies, 27(93%) of 
which were the result of wound infection. Complications occurred significantly 
more frequently when biopsies were performed below the waist compared with 
above the waist, in the ward compared with the outpatient operating theatre, in 
smokers compared with nonsmokers, and in those taking corticosteroids 
compared with those who were not.  Wertheim HFL et al35 in the study on risk 
and outcome of nosocomial S. aureus bacteraemia in nasal carriers versus non-
carriers have shown that nasal carriers have a heightened risk of developing 
nosocomial S aureus bacteraemia. The study by Selwyn S et al36 has stressed 
the importance of cross-infection in patients with extensive infected lesions, and 
communal baths and hands of members of staff, acting as important agents in 
the spread of infection.  Colsky SA et al37 in their study on analysis of antibiotic 
susceptibilities of skin wound flora in hospitalized dermatology patients have 
shown that increase in oxacillin resistance among S. aureus from leg ulcers was 
due to the chronic nature of the wound and frequent antibiotic exposure. Many of 
the study patients had long-term treatment, including prior admissions as well as 
multiple courses of antibiotic therapy in the outpatient setting.  Klevens RM et al38 
in their study on invasive MRSA infection have shown that most MRSA were 
health care-associated, and that incidence was highest among persons 65 years 
and older and those who had had previous hospitalization within one year. Oie S 
et al39 in their study demonstrated MRSA contamination in the dermatological 
ward over inanimate objects which can pave the way for nosocomial spread to 
other patients.  
Improper antibiotic usage paves the way for development of multi-drug 
resistant organisms (MDRO) in hospitals like MRSA, VRE, certain GNB, 
including those producing extended spectrum beta-lactamases (ESBLs) and 
others that are resistant to multiple classes of antimicrobial agents. Increased 
lengths of stay, costs, and mortality also have been associated with MDROs.40  
 
NOSOCOMIAL INFECTIONS IN DERMATOLOGY 
 The patients in dermatology ward, with large areas of their skin denuded 
and thus with severely compromised barrier and immune function of the skin, are 
especially prone to develop sepsis.7 Skin lesions form excellent culture media for 
bacteria and are, therefore, very sensitive indicators of cross-infection. 
Furthermore, patients with infected skin lesions are believed to be important 
dispersers of pathogenic organisms. In a dermatology ward, therefore, conditions 
should be ideal for studying the mechanism of cross-infection.36  
The incidence of NI in dermatology patients varies between 2.5% to 
62.5%.6,26 In a prospective survey on NI conducted in Hua Shan hospital, China, 
Zhang Y et al26 reported an overall incidence of 13.1% of NI, the incidence being 
highest in the dermatology ward (19.8%).  
In a University hospital in Germany, among 1450 dermatology inpatients 
surveyed for NIs, 35 patients were identified to have 37 NIs. The overall 
incidence was 2.5 NIs per 100 patients and the incidence density was 1.9 NIs per 
1000 patient days. 21 patients developed SSIs at the rate of 2.1%. The site-
specific incidence rates (NI per 100 patients) were 1.4 for SSI’s, 0.5 for other soft 
tissue infections, and 0.07 each for urinary tract and bloodstream infection. 
Staphylococcus aureus (40%) was the commonest organism causing NI.6  
In a study conducted in dermatology inpatients in UK 1962, 62.5% 
developed NI mainly with S.aureus. Autogenous infection accounted for about 
one third of the cases. The reservoirs of infection in the wards were the patients 
with extensive skin lesions. The communal baths and hands of members of staff 
seemed to be important agents in the spread of infection.36  
 Among 150 patients surveyed during a three month period in a 
dermatology ward in Delhi, India. Staphylococcus spp. was the commonest 
isolated organism out of which 80% (16/20) were MRSA. Ten patients developed 
sepsis with an incidence of 6.6%. Gram negative isolates included Acinetobacter 
spp, Pseudomonas aeruginosa and Klebsiella pneumoniae. Three patients died 
following sepsis.7  
 Nair et al 41, has reported a 3.58% mortality rate due to dermatological 
diseases. Patients with pemphigus group of diseases were the leading cause of 
mortality. Most of the patients were elderly (61-70years) and ten patients had 
more than 70% skin involvement which were risk factors for mortality. 
 
NOSOCOMIAL PATHOGENS 
Staphylococcus aureus 
Staphylococcus aureus is one of the most common causes of both 
endemic and epidemic infections acquired in hospitals, which result in substantial 
morbidity and mortality. MRSA and MSSA are equally pathogenic and are 
capable of causing the same spectrum of nosocomial infection.42 MRSA was first 
isolated in the US in 1968.  By the early 1990s, MRSA accounted for 20%-25% 
of S. aureus isolates from hospitalized patients. In NNIS system, among the S. 
aureus isolates from ICUs more than 50% was MRSA in 1999 which rose to 
59.5% in 2003.40 
 
Prevalence studies 
Kaplan et al43 in their surveillance study of community acquired S. aureus 
in children found that the number of community acquired MRSA (CA-MRSA) 
isolates and community acquired MSSA (CA-MSSA) isolates increased annually, 
but the rate of increase was greater for CA-MRSA. An antibiotic surveillance 
study by Colsky et al37 reported that in superficial skin wounds S. aureus 
comprised 77% of isolates and in leg ulcers 43%. Fifty percent of S. aureus 
isolated from leg ulcers were resistant to oxacillin.  A study from the bacteraemia 
reporting system in Britain showed a rise of MRSA infection from 1.8% between 
1989 and 1991 to 8.1% by 1994 and to 13.5% in 1995.44 A similar rise in MRSA 
bacteremia was seen in children less than 15 years of age in the UK from 0.9% 
in 1990 to 13% in 2000.45 
Lin KS et al46 reported that the proportion of NI due to S. aureus had 
increased from 9.8% in 1985 to 16.7% in 1994. Adwan K et al47 from Palestine 
reported a prevalence of 8.7% of MRSA in NIs, among which 39.3% were 
isolated from skin ulcers. Shigeruko I et al48 from Japan reported an MRSA 
prevalence of 35.6% in a hospital, of which 27.8% were cultured from 
dermatology inpatients. A surveillance program of invasive MRSA from US 
reported that 58.4% were community-onset infections and 26.6% were hospital-
onset infections.49 
A prospective study of community-acquired primary pyodermas in 
Mumbai, India showed that S. aureus was the predominant pathogen isolated 
(81.4%). Barring one, all strains were sensitive to methicillin.50 A prospective 
study done in Karnataka, India showed that among S. aureus infections reported, 
18.1% had infection with MRSA. Clindamycin-susceptible MRSA accounted for 
61.9% of cases. 46.1% patients were community-acquired MRSA and these 
were susceptible to multiple antibiotics, as compared to nosocomial isolates.51 A 
six month pilot programme on MRSA surveillance in India in 1994 showed a 
prevalence of 32% among large hospitals in India.52 According to the National 
Staphylococcal Phage Typing Centre, New Delhi, India there is an increase in 
the occurrence of MRSA from 9.83% in 1992 to 45.44% in 1998.53 Methicillin 
resistant S. aureus strains were more common in southern India (30.94%) than in 
the west (20.33%) or north (18.88%).53  In a study conducted among orthopedic 
and burns inpatients of a hospital in New Delhi, India in 1998, S. aureus was 
isolated in 41.8%,  of which 51.6% were found to be  MRSA. 87.3% of isolates 
were hospital-acquired and all were susceptible to vancomycin.54 A prevalence 
study of MRSA from major southern districts of Tamilnadu, India done from 2000-
2002 showed that among S. aureus isolates 31.1% of clinical samples and 
37.9% of carrier samples were found to be MRSA respectively. All the strains 
were sensitive to vancomycin.55 Mulla S et al56 in 2004, from a study done in a 
tertiary care centre, in Gujarat, India reported an MRSA prevalence of 39.50%. 
 
Outbreak study 
Balslev U et al57 from Denmark in 2000 reported an outbreak of borderline 
oxacillin-resistant S. aureus (BORSA) in a dermatological unit. BORSA was 
isolated in 37 samples from 11 patients, following which intervention was initiated 
focusing on infection control. It was observed that the patients with BORSA had 
more severe skin disease, were more often hospitalized, and had more bed 
days. Helali NE et al58 reported an outbreak of staphylococcal scalded skin 
syndrome (SSSS) in neonates from a maternity unit in France. Over a three-
month period, 13 neonates developed SSSS. The probable transmission 
occurred from an ancillary nurse who suffered from chronic dermatitis on her 
hands that favoured S. aureus carriage.  
An outbreak of MRSA was reported in dermatology indoor patients in 
2002, from Mumbai, India. Out of 63 indoor admissions, MRSA isolates were 
detected in 10 patients, all of whom had erosive or purulent skin lesions. Three of 
these patients were nasal carriers of MRSA.59 
 
Nasal carriage studies 
The anterior nares are reservoirs for S.aureus. Mucin appears to be the 
critical surface that is colonized in a process involving interaction between 
staphylococcal protein and mucin carbohydrate. Three patterns of carriage can 
be distinguished: Sixty percent of population harbours S. aureus intermittently, 
and the strains change with varying frequency; twenty percent almost always 
carry a strain and are persistent carriers and another 20% almost never carry S. 
aureus.42 
In a prospective study of inpatients in Texas, USA in 2002, 21.5% were 
initially colonized with S. aureus.  The incidence of subsequent MRSA infection 
for those initially colonized with MRSA was close to 10 times the incidence for 
patients colonized with MSSA or not colonized with S. aureus at admission.60 A 
survey of staphylococcal carriage in the dermatological and burns units in the UK 
showed that 20% of patients in the dermatology ward carried MRSA at admission 
compared to 55.6% in patients in the burns unit.61  Kuehnert MJ et al62 in a study 
done in the USA in 2001-2002 reported a national prevalence of S. aureus and 
MRSA colonization estimates of 32.4% and 0.8% respectively. Saxena S et al63 
in a community prevalence study of MRSA in  East Delhi, India in 2002 reported 
an S.aureus nasal carriage of 29.4% with a colonization rate ranging from 10% to 
more than 40% in a normal adult population.  Majumder et al64 studied the 
prevalence of MRSA in a referral hospital in Assam. They found a methicillin 
resistance of 52.9% among S. aureus isolates and 15% among coagulase 
negative staphylococci. 
 
Coagulase-negative staphylococci     
  Coagulase-negative staphylococci are among the most commonly 
isolated bacteria in clinical microbiology laboratories. Such coagulase-negative, 
novobiocin-susceptible staphylococci as Staphylococcus epidermidis have 
emerged as a major cause of infection, particularly in hospitalized patients with 
indwelling foreign bodies and in immunocompromised patients.65 
 
Enterococcus species 
 Vancomycin-resistant enterococci (VRE) are formidable organisms 
renowned for their ability to cause infections with limited treatment options and 
their potential for transferring resistance genes to other Gram-positive bacteria. 
They are usually associated with NIs.66 From 1990 to 1997, the prevalence of 
VRE in enterococcal isolates from hospitalized patients increased from <1% to 
approximately 15%. VRE accounted for almost 25% of enterococcus isolates in 
NNIS ICUs in 1999 (94), and 28.5% in 2003.40  Bhavnani SM et al67 in a case 
control study found the following factors to be highly associated with VRE 
bacteremia: positive HIV status and AIDS, drug abuse, prior exposure with 
parenteral vancomycin, and history of liver transplant.  Usually associated with 
NI, VRE are rarely reported as a cause of community-acquired infection.66 
 
Gram negative infection 
 During the past 20 years, there is an increasing frequency of GNB 
associated hospital-acquired infection.68 Gram negative bacilli cause four major 
types of hospital-acquired infection: pneumonia, surgical site infection (SSI), 
urinary tract infection (UTI), and bloodstream infection (BSI).68 Data analysis from 
the NNIS system from 1986-2003 to determine the most frequent types of 
hospital-acquired infection in ICUs  showed that GNB were associated with 
23.8% of BSIs, 65.2% of pneumonia episodes, 33.8% of SSIs, and 71.1% of 
UTIs. The proportion of ICU pneumonia episodes associated with Acinetobacter 
species increased from 4% in 1986 to 7.0% in 2003 (P<.001). The rate of 
antimicrobial resistance is especially increasing among Acinetobacter species 
and P.aeruginosa.68  
 Malik A et al23 in a study on NI in newborns found that the commonest NI 
was septicaemia which was observed in 45 cases followed by umbilical sepsis in 
7.4%. GNB were isolated in nearly 70% of the cases with Klebsiella being the 
commonest organism causing the infections, accounting for 55.6% of the cases.  
A prospective survey on NIs in China which included dermatology patients 
revealed that 66.4% of the nosocomial pathogens were GNBs. They comprised  
P.aeruginosa (13.3%), K.pneumoniae (12.2%), E.coli (8.9%) and acinetobacter 
(7.7%).26 Dettenkofer M et al6 in their study on nosocomial infections in 
dermatology inpatients found that E.coli comprised 18% of the isolates among 
SSIs.  Sharma VK et al7 in their study on sepsis in dermatology wards found  48 
bacterial isolates in culture from different sites out of which 28 were GNBs. They 
comprised acinetobacter in 9 cases, pseudomonas and klebsiella in 6 cases 
each and E.coli and proteus in 7 cases each. These isolates were most sensitive 
to a combination of piperacillin and tazobactam (100%) followed by 
cefoperazone-sulbactam (88.9-100%), imipenem (62.5-100%), and meropenem 
(62.5-83.3%). Amikacin,  ciprofloxacin,  piperacillin, netilmicin,  ceftazidime and 
ticarcillin-clavulanic acid showed low sensitivity.  Mehta et al69 in their study on 
bacterial isolates in burn wound infections found that during the period from 
2002-2005 pseudomonas species (51.5%) was the commonest pathogen 
isolated followed by acinetobacter species (14.28%).Pseudomonas species was 
moderately resistant to piperacillin (41.2%) where as resistance was more 
marked with antimicrobials like amikacin(85.18%), gentamicin(89.22%), 
ciprofloxacin(78.81%), carbenecillin (88.26%), tobramycin(87.52%) and 
ceftazidime(79.09%).  
 Gram negative bacilli with extended-spectrum beta lactamases (ESBLs), 
resistant to  fluoroquinolones, carbapenems, and aminoglycosides also have 
increased in prevalence. The resistance rates for K.pneumoniae to ceftazidime 
and other third-generation cephalosporins have varied from 3.6 % (United 
States) in 1997 to 20.6% (NNIS) ICUs in 2003.40 Between 1999 and 2003, 
Pseudomonas aeruginosa resistance to fluoroquinolone antibiotics increased 
from 23% to 29.5% in NNIS ICUs.40  Also, a 3-month survey of 15 Brooklyn 
hospitals in 1999 found that 53% of A. baumannii strains exhibited resistance to 
carbapenems and 24% of P. aeruginosa strains were resistant to imipenem.40 A 
retrospective analysis of 5039 pus samples obtained from inpatients at AIIMS, 
New Delhi in 2002 found that 54.04% of isolates were GNB. Out of them 14.49% 
were sensitive to all antibiotics. ESBL production was observed in 66.75% of 
isolates and ranged from 40.6% in Proteus to 76.34% among Klebsiella 
species.70 
 
 
Viral infection 
Any viral infection can spread within hospitals. It can cause viral 
respiratory infection, outbreaks of diarrhoea, cross infection with blood-borne 
viruses in both patients and hospital staff.11 Since identification of nosocomial 
viral infections depends on both laboratory detection and surveillance intensity, 
hospitals without diagnostic virology lab support will be unlikely to detect most of 
these infections.5  
In dermatology, patients with large areas of skin involvement are prone to 
develop Kaposi’s varicelliform eruption (KVE) a distinct cutaneous eruption 
caused by herpes simplex virus (HSV) Type I and Type 2 and rarely by 
coxsackie A16 virus and vaccinia virus over preexisting dermatoses.  The most 
common predisposing condition for KVE is atopic dermatitis, but it has also been 
described in various dermatoses with impaired barrier function like Darier’s 
disease, pemphigus and burns. HSV spreads by droplet infection or by direct 
contact. A mini outbreak of five cases of KVE was reported from the skin ward in 
Vishakhapatnam, Andhra Pradesh in May 2005. This occurred in a makeshift 
ward after admission of the first case.71 There are several reports of HSV out 
breaks especially in infants under 30 days and patients with burns. Any patient 
with skin failure has an increased risk as it is easy for entry of HSV.72 There are 
several reports of HSV 1 outbreaks with transmission either through patients, 
hospital personnel or due to hospital environment.73,74,75 
Spread of blood-borne viruses, particularly hepatitis B and C and HIV, is of 
greatest concern. Infected patients are not always recognized, and every 
procedure involving blood (phlebotomy, surgery, dialysis, endoscopy, 
transfusion) carries a risk of spread of infection to hospital staff or other 
patients.11 
 
Fungal infection 
Nosocomial fungal infections are commonly seen in patients with iatrogenic 
immunosuppression for organ transplantation, and with AIDS, and in oncology 
wards, high risk nurseries, burn and trauma wards.76 Some exposures act 
primarily by inducing immunosuppression (e.g., corticosteroids, chemotherapy, 
malnutrition, malignancy, and neutropenia). Other exposures primarily provide a 
route of infection (e.g., extensive burns, indwelling catheter) or a combination of 
factors. Centre for Disease Control (CDC) has reported a steady increase in the 
rate of nosocomial fungal infections from 5.4% in 1980 to 9.9% in 1990.77 The 
majority of nosocomial fungal infections are reported to be caused by Candida 
spp. The data from NNIS during 1980 to 1990 shows that Candida infections 
accounted for 78.3% of fungal NI, followed by Torulopsis glabrata (7.3%), and 
Aspergillus spp. (1.3%).70 Newly recognized pathogenic fungi some previously 
thought to be nonpathogenic, including Malasezzia spp., non-albicans Candida 
spp., Fusarium spp., trichosporon spp., Mucor and Rhizopus spp., and Alternaria, 
Bipolaris, and Curvularia spp also have been reported as the cause of Nis.76 
 Only a few reports of incidence of, and spectrum of organisms responsible 
for candidemia in India are available.78 A recent study done in Delhi reported 7 
cases of candidemia out of 101 BSI. Three (42.8%) were infected with C. 
albicans and the rest with non-albicans species.79 In a recent 5 year retrospective 
study of candidemia from AIIMS, Delhi, the majority (80%) of episodes was 
caused by non-albicans species.78  In the study by Sahni et al79 all the patients 
with candidemia were admitted in the ICUs. Five (71.4%) patients died. Amongst 
the risk factors, the length of hospitalization, use of broad-spectrum antibiotics, 
central venous catheters, mechanical ventilation, and total parenteral nutrition 
were found to be significantly related to acquisition of nosocomial candidemia. 
Luzzati R et al80 in a retrospective study have reported an average incidence was 
1.14 episodes per 10,000 patient–days per year. Increased age, hospitalization 
in an intensive care unit, a longer duration of indwelling central lines, and 
inadequate antifungal therapy were significantly associated with poor outcome. 
Archer-Dubon C et al81 have reported an epidemic outbreak of Malassezia 
folliculitis in three patients in an intensive care unit. 
 
PREVENTION OF NOSOCOMIAL INFECTION 
Infection control is the responsibility of all health care professionals — 
doctors, nurses, therapists, pharmacists, engineers and others. Hand washing is 
said to be the single most critical measure in preventing spread of organisms 
such as MRSA, yet compliance is generally poor.11 Isolation and barrier nursing 
are used generally for patients known to be infectious (e.g with tuberculosis, 
MRSA, or active diarrhoea). Source isolation is done to prevent the transfer of 
microorganisms from infected patients, who may act as source of infection to 
staff or other patients. Protective isolation is done for some immunocompromised 
patients to protect them from infection, rather than to protect their contacts.2 
Adequate bed-spacing, barrier nursing and isolation of suspected cases are 
mandatory to prevent life-threatening infections such as KVE.71 Herpes simplex 
virus transmission is easily prevented by appropriate barrier methods and 
decontamination of surfaces.72  Oie S et al39 studied the contamination of 
environmental surfaces by S. aureus in the dermatological ward of a university 
hospital. They found 100-105 CFU of MRSA or MSSA on items such as 
immersion bath tub, foot wash bowl, stretcher for immersion bath, and chair for 
shower. After disinfection, no S. aureus was detected on smooth surfaces; 
however they were detected on porous surfaces made of sponge like material 
such as the stretcher and the shower chair. In patients with S. aureus bacteremia 
there is as strong correlation between strains colonizing the nares, strains 
isolated from foci of infection, and strains isolated from blood, suggesting that S. 
aureus bacteremia may have an endogenous origin. Strategies to interrupt their 
transmission by elimination of nasal carriage may prevent systemic infections.  In 
several studies nasal treatment with mupirocin led to a reduction by a factor of 
four in the incidence of S.aureus bacteremia per patient year in carriers receiving 
haemodialysis.42 Engineering and design considerations are an important part of 
control of NI. Simple factors such as the availability of sinks for hand washing 
and over crowding of patients can have a significant effect on the ability of staff to 
prevent cross infection.11 
 
 
Summary of prevention methods of NI  
1. Limiting transmission of organisms between patients in direct patient care 
through adequate hand washing and glove use, use of clean bed linen 
and appropriate aseptic practice, isolation strategies, sterilization and 
disinfection practices. 
2. Controlling environmental risks for infection 
3. Protecting patients with appropriate use of prophylactic antimicrobials, 
nutrition, and vaccinations. 
4. Limiting the risk of endogenous infections by minimizing invasive 
procedures. 
5. Surveillance of infections, identifying and controlling outbreaks. 
6. Prevention of infection in staff members. 
7. Enhancing staff patient-care practices, and continuing staff education.11 
 
 
MATERIALS AND METHODS 
 
STUDY DESIGN : A prospective cohort study  
 
STUDY SETTING : The study was conducted in the dermatology inpatient ward 
of Christian Medical College Vellore, a tertiary care centre, in Tamil Nadu. The 
dermatology ward included a general ward of 20 beds (a room with 5 beds for 
females, 2 rooms with 7 beds each for males and a single room), isolation ward 
and 2 private ward blocks with single and double bed rooms. 
 
STUDY SUBJECTS: The patient population included all patients admitted under 
the department of Dermatology, Venereology and Leprosy during the study 
period. 
Inclusion criteria:  
  All inpatients who were admitted with skin diseases to the                
dermatology ward during the study period and who gave informed consent               
were included in the study. 
 
Exclusion criteria: 
Patients who had been hospitalized 10 days prior to the present 
episode of hospitalization  
Patients hospitalized for < 48 hours 
Patients who did not give informed consent to participate in the study. 
 
DURATION OF STUDY: Patients were recruited in the study from 1st November 
2006 till 15th September 2007. 
 
METHODOLOGY:  
 A preliminary study was conducted from July 2006 to October 2006 (four 
months). A total of 156 inpatients were studied, out of which 9 patients developed 
NI.  During the preliminary study, it was noted that since the growth of bacterial 
isolates were not quantified, colonization and infection could not be differentiated. 
Hence it was decided to do four streak method of semi-quantitative culture for the 
next study period. All inpatients who gave written informed consent (annexure I) 
were examined by the principal investigator. Demographic details, which included 
age, gender, occupation, height, weight, body mass index, date of admission and 
discharge were recorded in a questionnaire (annexure II). A detailed history at 
admission which included duration of dermatological illness (acute illness was 
arbitrarily defined as illness <6 weeks and chronic illness as >6 weeks), presence 
of  co-morbid illnesses like diabetes mellitus, essential hypertension, obesity, 
anemia, HIV infection, history of previous hospitalization and details of previous 
treatment including intake of antibiotics 2 weeks prior to hospitalization, oral 
steroid intake (>40mg/day for more than 1 week or >20mg/day for more than 2 
weeks), steroid sparing immunosuppressives (methotrexate, azathioprine or 
cyclophosphamide) were recorded. Clinical parameters assessed at admission 
included pulse rate, respiratory rate, blood pressure and body temperature. 
Systemic examination was done in all patients. Type of skin lesions, presentation 
of primary and secondary skin lesions and body surface area involvement were 
noted. If the patient had symptomatic signs of infection at admission, appropriate 
investigations like Gram’s stain from pus, pus culture, urine routine and cultures, 
chest X ray, blood or sputum cultures were done according to the site of 
infection. Signs of infection included infection of lesions with either presence of 
pain or tenderness, localized swelling, surrounding erythema, increased warmth, 
pus discharge and/or systemic signs of infection like associated fever, 
tachycardia, tachypnoea or organ dysfunction, Patients were started on empirical 
antibiotic therapy based on initial Gram’s stain of the specimen. The antibiotic 
was appropriately changed based on the final culture reports. Invasive 
procedures including intravenous cannulation, skin, lymph node and bone 
marrow biopsies were recorded. All the patients with diseases which predispose 
to skin failure were provided strict reverse barrier nursing, dilute potassium 
permanganate cleansing for skin lesions and alcohol (propanol) based hand 
disinfectant to prevent transmission of infection while in the ward. The patients 
were followed up daily after the admission till discharge by the principal 
investigator. The patients were identified as having NI according to CDC 
guidelines (annexure III) based on symptoms and signs of infection. The first 
episode of infection identified 48 hours after admission and not present at 
admission was diagnosed as NI. The time to onset from day of admission was 
recorded. Appropriate investigations (total and differential counts, pus Gram’s 
stain and culture, urine routine, urine culture, blood culture, sputum Gram’s stain 
and culture, and chest X ray) were sent, depending on the site of infection. 
Cultures were not performed on patients who had no frank pus discharge or 
cellulitis. If the intravenous site was infected (erythema, edema, tenderness), the 
intravenous line was disconnected and the catheter tip sent for culture. Once the 
antibiotic susceptibility pattern was obtained, the antibiotics were continued or 
changed accordingly. The patients’ condition at discharge and the drugs given 
were recorded. The patients were followed up 1 week after discharge in the 
dermatology outpatient department. 
 
Method of taking cultures 
Pus culture 
 Pus was collected aseptically using at least 2 swabs in a sterile test tube, 
from pustules, turbid blisters and/or abscesses. Tissue culture samples were 
taken from chronic ulcers. Smears were prepared and subjected to Gram’s 
staining. For quantification of colonies, four streak methodology was undertaken. 
 Pus culture four streak semi-quantification: The wound was cleansed with 
saline and all debris removed. The pustules/ turbid blisters/ healthy looking 
granulation tissue was swabbed in a zigzag pattern, gently rotating the tip of the 
swab. Swabs were transported in culture tubes to the laboratory. The swab was 
then inoculated on to the primary culture media, blood agar (BA), chocolate agar 
(CA), MacConkey agar plates (MA) and Thioglycolate broth (TB) in the laboratory 
and streaked in four quadrants. The results were interpreted as scanty growth 
(<20 colonies), moderate (20-100 colonies) and heavy growth (>100 colonies).82 
MA and TB plates were incubated at 37º C. BA and CA were incubated in CO2 
atmosphere at 37° C. The plates were read after overnight incubation. Smears 
were prepared from the different types of colonies. If the isolate was identified as 
Staphylococcus species, the following tests were done for further identification: 
slide test for clumping factor, tube-coagulase test and mannitol fermentation test. 
If gram negative organisms were identified mannitol motility medium, triple sugar 
iron agar, peptone water for indole test and Simman’s citrate agar were used for 
further identification. Antibiotic sensitivity test was done for all isolates.83    
Antimicrobial susceptibility was performed on Mueller-Hinton agar by the 
Kirby-Bauer method of standard disk diffusion method. For gram-positive 
organisms the antibiotics tested were: Oxacillin (1ug), erythromycin (15ug), 
gentamicin (10ug), chloramphenicol (30ug), penicillin (10ug), vancomycin (30ug), 
teicoplanin (30ug), netilmicin (30ug), rifampicin (5ug), linezolid (30ug).  
For gram-negative organisms the antibiotics tested were: Ampicillin (10ug), 
cefuroxime (30ug), ciprofloxacin (5ug), gentamicin (10ug), amox/clavulanic acid 
(20/10ug), cotrimoxazole (25ug), cefotaxime (30ug), ceftazidime (30ug), 
amikacin (30ug), nalidixic acid (30ug), nitrofurantoin (300ug), norfloxacin (10ug), 
imipenem (10ug), meropenem (10ug), cefaperazone-sulbactam (75/30ug), 
piperacillin-tazobactam (100/10ug) and cefpodoxime (10ug). If the isolate was 
resistant to the first line panel of antibiotics, then the second line antibiotics were 
tested at request. The disk strengths used were recommended by the Central 
Laboratory Standard Institutional guidelines (CLSI).84 
 In polymicrobial isolates, scanty or moderate growth was considered as 
colonization if it was from open erosion while any bacterial isolate was 
considered significant if culture was taken from an intact lesion like a pustule or 
turbid blister. Growth of coagulase negative staphylococci and diphtheroids were 
not considered as pathogenic. 
Blood culture 
In patients in whom septicaemia was suspected, blood culture was done. 
A blood sample was drawn with full aseptic precaution and received in bottles 
containing the culture medium. The bottles were incubated in BacT-alert system. 
If growth was present, it was indicated by an alarm. Smears were done from the 
colonies, subjected to Gram’s stain and cultured in appropriate media for 
identification.83 
 
Urine culture 
In patients suspected to have urinary tract infection, a clean-catch mid- 
stream urine sample or supra-pubic aspirate were obtained in a sterile bottle and 
transported immediately to the laboratory.  It was inoculated into both blood and 
MacConkey agar plates.  According to the number of colonies, growth was 
quantified as probably significant if colony count was 10 3 - 10 5 CFU/ml and 
significant if >10 5 CFU/ml .83  
 
Faeces culture 
In patients with loose stools, a stool sample was collected in a sterile 
screw-capped bottle. For all watery stool samples a hanging drop preparation 
was done and examined immediately. Specimens were cultured on plates with 
blood agar, Desoxycholate citrate agar and MacConkey agar. Biochemical tests 
were done for further identification.83  
 Viral culture 
 If a patient was suspected to have herpes infection, a Tzanck smear and 
herpes culture from the vesicles/erosions were done for identification of the 
same. 
 
Total hospital nosocomial infection surveillance 
 Surveillance of NI among the hospital inpatients was done by a nurse who 
was trained in NI surveillance and was monitored by the Hospital Infection 
Control Committee (HICC). The nurse visited each ward once a week. A record 
of the number of patients in the ward at the time of visit was kept. The ward 
nurse’s record and individual patient charts were reviewed to check for patients 
with fever on that day. A patient who developed fever more than 48 hours after 
admission, was evaluated for NI. The predisposing factors, site of infection, 
microbiological and radiological evidence and the clinical course of the patient in 
the hospital were recorded and categorized into different types of NI.  
 
STATISTICAL ANALYSIS 
 All the parameters were entered in a data base and analysis was done 
with SPSS (11) Software Version.  
SAMPLE SIZE 
Sample size was calculated by using the formula: 
                  n= 4pq 
                          d² 
 where  p=anticipated proportion 
           q= (1- p) 
           d²= precision (or) width of confidence interval 
 
The number required to estimate an anticipated incidence of 1.1% with 1 
unit precision of 95% confidence is 396. Each patient with NI was compared with 
two randomly selected controls from the study population who did not develop NI. 
The comparison of the risk factors between the cases and controls was done 
using t test, Mann-Whitney test and Chi-square test. Kaplan-Meier product limits 
estimates for survival were used to construct the graph of time to onset of NI. 
Odds ratio were also calculated. Multivariate logistic regression analysis was 
done using those variables which were significant in the univariate analysis.  
 
Research Committee approval 
This study was approved by the institutional research committee. 
 
RESULTS 
 
Demographic and clinical profile of study patients:  
A total of 421 patients were admitted during the study period of which 
there were 260 males and 161 females. Their age ranged from 4 months to 84 
years [mean 39.53 ± SD 18.42] (figure 1). 
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The details of underlying primary dermatological diagnosis of the study group are 
given in table 4. The most common dermatological condition was psoriasis which 
was seen in 71 patients (16.86%) followed by autoimmune-bullous disorders in 
50 (11.87%), and Hansen’s disease in 43 patients (10.21%). Out of 421, 144 
(34.2%) patients had diseases which predisposed to skin failure. 
 
Table 4:  Profile of primary dermatological disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis 
No. of 
Patients 
(%) 
Psoriasis 71 (16.86) 
Autoimmune-bullous 
disorder 50  (11.87) 
Other dermatoses 44 (10.45) 
Hansen’s disease 43 (10.21) 
Allergic contact dermatitis 36 (8.55) 
Drug reactions 31 (7.36) 
Viral diseases 30 (7.12) 
Erythroderma 22 (5.22) 
Atopic dermatitis 21 (4.98) 
Urticaria 20 (4.75) 
Chronic leg ulcer 13 (3.08) 
Vasculitis 11 (2.61) 
Vitiligo 8 (1.90) 
Cellulitis 7 (1.66) 
Panniculitis 6 (1.42) 
Skin malignancy 4 (0.95) 
Connective tissue disorder 4 (0.95) 
Co-morbidity:  
  Among 421 patients, 264 (62.7%) had co-morbidities. The various co-
morbid diseases seen in our patients is shown in table 5. Diabetes mellitus and 
hypertension were present in 15.91% of patients each. 82 patients had more 
than one co-morbid condition. 
Table 5:  Total number of patients with co-morbid illness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-morbid 
condition 
Number of 
patients 
(%) 
Type II Diabetes Mellitus 67 (15.91) 
Essential Hypertension 67 (15.91) 
Anemia (iron deficiency/ 
chronic disease) 32 (7.60) 
Dyslipidemia 19 (4.51) 
Obesity 15 (3.56) 
COPD 13 (3.09) 
Osteoarthritis 12 (2.85) 
Hypothyroidism 11 (2.61) 
Tuberculosis 10 (2.38) 
HIV infection 8 (1.90) 
Seizure disorder 6 (1.43) 
Osteoporosis 4 (0.95) 
INFECTION AT ADMISSION 
One hundred and nineteen (28.26%) patients were clinically diagnosed to 
have infection at admission of which 74 were males (62.18%) and 45 (37.81%) 
females. Their ages ranged from 1-75 years (mean 38.95 ± SD 21.36). The 
details of their underlying diseases are given in table 6. 
 
Table 6: Disease profile of patients with infection at admission 
Diagnosis No. patients (%) 
Autoimmune-bullous disorder 25  (21.00) 
Other dermatoses 20 (16.80) 
Psoriasis 20 (16.80) 
Atopic dermatitis 10 (8.40) 
Allergic contact dermatitis 9 (7.56) 
Cellulitis 7 (5.88) 
Drug reactions 6 (5.04) 
Chronic leg ulcer 6 (5.04) 
Erythroderma 5 (4.20) 
Viral diseases 4 (3.36) 
Vasculitis 4 (3.36) 
Hansen’s disease 2 (1.68) 
Vitiligo 1 (0.84) 
Total 119 (28.26%) 
 
 
Seventy (58.83%) out of the 119 patients who were admitted with 
infection, had appropriate culture and susceptibility testing done as shown in 
table 7. Cultures could not be sent in 49 patients (41.17%). Nine of these patients 
had primary pyoderma and 40 had secondary pyoderma.  
  
Table 7: Bacterial isolates in cultures from different sites from patients with infection at 
admission 
Organism Pus(skin) Urine Blood Stool Total 
Staphylococcus aureus 31  1  32 
Beta haemolytic Streptococcus 14    14 
Enterococcus 3    3 
Escherichia.coli 7 1   8 
Pseudomonas aeruginosa 6    6 
Klebsiella spp. 4    4 
Non fermenting gram negative 
bacilli (NF GNB) 
3    3 
Enterobacter spp. 3    3 
Proteus mirabilis 3    3 
Morganella morgagni 1    1 
Shigella sonnei    1 1 
Citrobacter freundii 1    1 
Total 76 1 1 1 79 
 
The commonest gram positive isolate from the skin included S.aureus in 31 
patients (40.78%), followed by beta hemolytic Streptococci in 14 (18.42%). The 
commonest gram negative bacterial skin isolate was E. coli in 7 (9.21%) patients 
followed by P.aeruginosa in 6 (7.89%) patients. 
 
Susceptibility pattern of gram positive organisms 
 The susceptibility pattern of gram positive organisms isolated from 
patients with infection at admission is shown in table 8. Out of 32 isolates of 
S.aureus, 9 (28.13%) were MRSA. All isolates of MRSA were susceptible to 
rifampicin, vancomycin, linezolid and teicoplanin. All the three isolates of 
Enterococcus  were resistant to erythromycin and 1 (33.33%) of the isolates was 
also resistant to gentamicin. 
Table 8: Susceptibility pattern of Gram positive organisms isolated from patients with 
infection at admission 
Organisms S. aureus Beta haem Strepto Enterococcus 
Total isolates 32 14 3 
Susceptibility S % R % S % R % S % R % 
Gentamicin         2 66.67 1 33.33 
Chloramphenicol             
Erythromycin 16 50.00 16 50.00 14 100     3 100 
Oxacillin 23 71.88 9 28.13         
Penicillin     14 100       
Ampicillin         3 100   
 
 
Susceptibility pattern of gram negative organisms 
 Of the 6 isolates of P.aeruginosa all were susceptible to amikacin and 
ceftazidime and 2 (33.33%) showed resistance to ciprofloxacin. Of the 3 isolates 
of NFGNB, 1 (33.33%) was resistant to gentamicin, amikacin, ceftazidime and 
ciprofloxacin. Five out of 8 (62.5%) isolates of E..coli  were resistant to co-
trimoxazole, 4 (50%) to ciprofloxacin and augmentin and 1 (12.50%) to 
gentamicin. All the isolates of Klebseilla spp.  were susceptible to gentamicin, 
cefuroxime, ciprofloxacin and co-trimoxazole and only one was resistant to 
augmentin. All the isolates of Enterobacter spp. (3), Citrobacter freundii (1), 
Proteus mirabilis (3) and Morganella morgagni (1) were susceptible to 
gentamicin. 
 
Invasive Procedures 
 Of the 421 patients, 115 underwent invasive procedures while in the ward. 
 
NOSOCOMIAL INFECTION 
 Seventeen of the 421 patients developed NI. The incidence of NI in the 
dermatology ward was 4.05 infections/100 discharges and NI incidence rate was 
6.24 infections/1000 hospital days. The total hospital incidence of NI during the 
same period was 0.57/100 discharges and the comparison is shown in figure 2. 
Fig. 2: Comparison of incidence of NI among dermatology and total hospital inpatients 
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 The median time to onset of NI was 11 days (IQR 8.10, 13.90) as shown 
in figure 3. 
Fig 3: Time to onset of NI 
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Profile of patients with NI: 
Of the 17 patients with NI, 11 (64.7%) were males and 6 (35.30%) 
females. The age ranged from 20-70 years (mean 42.06 ± SD 14.8), two patients 
were more than 60 years of age.  Five patients were over weight (BMI >25). The 
body surface area (BSA) involvement varied from 1-100% (median 21, range 10-
65) with more than 30% involvement in ten cases. The duration of dermatoses 
varied from 3 days to 15 years.  In acute dermatoses, it varied from 1 week to 4 
weeks (n = 3); while in chronic dermatoses, it ranged from 2 months to 15 years 
(n = 14). 
The underlying dermatological disease profile of patients with NI is given 
in table 9.  Nosocomial infections were seen more in patients with autoimmune-
bullous disorders (14%), followed by erythroderma (9.09%) and psoriasis 
(4.22%) respectively. 
 
Table 9:  Dermatological diagnosis of patients with NI 
Primary dermatological 
diseases 
Total study 
group (421) 
No. patients 
with NI (17)  
(%) of 
patients 
Autoimmune-bullous disorder 50 7  14 
Erythroderma 22 2  9.09 
Psoriasis 71 3  4.22 
Other dermatoses 278 5  1.79 
 
 
The comorbid conditions seen in these patients were essential 
hypertension and hypoproteinemia in four patients each, type II diabetes mellitus, 
chronic kidney disease and anemia (iron deficiency / chronic disease associated) 
in two patients each and hypothyroidism, HIV infection and ulcerative colitis in 
one patient each respectively.  
Of the 119 patients who were admitted with infections, 10(8.4%) 
developed an NI. 
Risk factors among patients with NI: 
There was history of oral antibiotic intake 2 weeks prior to admission in five 
patients. Eleven patients were on steroids / immunosuppressives agents of 
whom 2 were on oral steroids, 3 had a combination of oral steroids with steroid 
sparing immunosuppressants, 4 were on steroid sparing immunosuppressants 
and 2 were on DCP pulse.  
The duration of hospitalization for patients who developed NI was (median 
21 days, IQR [13, 25]). 
The invasive procedures underwent by the patients with NI are shown in 
table 10. 
Table 10: Invasive procedure done in patients with NI 
Procedure 
Total No. 
Patients 
Intravenous cannula (peripheral) 9 
Skin biopsy 8 
Lymph node biopsy 2 
Bone marrow biopsy 2 
Central line intravenous cannula 1 
 
BACTERIAL PATHOGENS CAUSING NI 
A total of 22 bacterial isolates were obtained from different specimens, 
pus (15), blood (1), urine (1) as shown in table 11. Source of NI in cases 
included, skin (pustules [11], furuncle [2]), lymph node abscess [n = 2]), blood 
stream infection [1], urine (supra-pubic aspiration) [1], 5 patients had 2 isolates.   
The commonly isolated organism from the skin was S.aureus 14/19 
(73.68%) followed by beta haemolytic streptococcus (2/19) 10.52%. One isolate 
each of E..coli and P.aeruginosa were grown from a single urine culture (supra-
pubic aspiration).  A solitary blood stream isolate of E.coli was seen. 
 
Table 11: Bacterial isolates in cultures from different sites at development of NI 
Organism Pus(skin) Urine Blood Total 
Staphylococcus aureus 14   14 
Beta haemolytic Streptococcus 2   2 
Enterococcus 1   1 
Pseudomonas aeruginosa  1  1 
Escherichia.coli  1 1 2 
Proteus mirabilis 1   1 
Non fermenting gram negative bacilli ( 
NF GNB) 1   1 
Total 19 2 1 22 
 
 
 
 
Susceptibility pattern:  
 The susceptibility pattern of gram positive and gram negative organisms 
causing NI are as shown in table 12 and table 13 respectively. Majority of the 
isolates of S..aureus 13/14 (92.9%) were methicillin-sensitive and only one was 
methicillin-resistant. The MRSA isolate was susceptible to linezolid, vancomycin, 
rifampicin and teicoplanin. The isolates of beta haemolytic Streptococci and 
Enterococcus were susceptible to first line antibiotics. 
  
Table 12: Susceptibility pattern of Gram positive organisms causing NI 
Organisms S.aureus Beta haemolytic streptococci Enterococci 
Total no. of 
isolates 14 2 1 
 S % R % S % R % S % R % 
Gentamicin         1 100   
Erythromycin 8 57.1 6 42.9 2 100   1 100   
Oxacillin 13 92.9 1 7.14         
Ampicillin         1 100   
Penicillin     2 100       
 
 
 
 
 
 
 
 
 
Table 13: Susceptibility pattern of Gram negative organisms causing NI  
Organisms P.aeruginosa E. coli Proteus mirabilis NFGNB 
Total no. of 
isolates 1 2 1 1 
 S % R % S % R % S % R % S % R % 
Ist line drugs 
Gentamicin   1 100   2 100   1 100     
Amikacin   1 100 2 100       1 100   
Ceftazidime   1 100   1  * 50     1 100   
Ciprofloxacin   1 100   2 100   1 100 1 100   
Co-trimoxazole       1* 50   1 100 1 100   
IInd line drugs                 
Imipenem   1 100 2 100           
Meropenem   1 100 1* 50           
Cefaperazone 
+sulbactum I 100   1* 50           
 
Susceptibility not done in 1 isolate. 
 
The isolate of P.aeruginosa showed resistance to all antibiotics with intermediate 
sensitivity to cefaperazone + sulbactam. All the isolates of E..coli (2/2,100%) 
were resistant to gentamicin and ciprofloxacin. Proteus mirabilis was resistant to 
all antibiotics. NFGNB was susceptible to ciprofloxacin and amikacin. 
 The comparison between cases and controls showing the various 
demographic profile, disease and other risk factors are shown in table 14A, table 
14B and table 14C respectively. 
  
 
 
Table 14: Risk factors of NI: cases and control 
Table 14 A: Demographic details 
      
                                              
Cases (17) Control (34) p value 
Age: 42.06 ± 14.8 42.50 ± 18.2  
0.931 
 
Sex:       
                                   Male
Female
 
11 (64.7) 
 
6  (35.3) 
 
18 (52. 9) 
 
16  (47.1) 
 
0.424 
BMI: 
                            Obese(>25)
Non-obese(<24.9)
 
5 (29.4) 
 
12 (70.6) 
 
11 (32.4) 
 
         23 (67.6) 
 
0.831 
 
Associated Diabetes mellitus: 
 
Yes
No
 
       
     
      2 (11.8) 
 
15 (88.2) 
           
      
          9 (26.5) 
 
25 (73.5) 
 
 
0.229 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 14 B: Disease profile  
                                                             Cases              Control             p value 
Primary Dermatological disease:  
Autoimmune-bullous disorder 
 
Erythroderma 
 
Psoriasis 
 
Others 
 
 
     7 (41.2%) 
 
2 (11.8%) 
 
3 (17.6%) 
 
5 (29.4%) 
 
    6 (17.6%) 
 
2 (5.9%) 
 
5 (14.7%) 
 
21 (61.8%) 
 
 
 
  0.15 
Body Surface Area Involvement 
(BSA%):                                                
                                      Median
Range
 
 
 
           30 
(10-65) 
 
 
        13 
(5-28.75) 
 
 
  0.086 
Duration of illness: (weeks) 
 
Acute   (<6 weeks) 
 
Chronic (>6 weeks) 
 
 
 
        3 (17.6) 
 
14 (82.4) 
 
 
      7 (20.6) 
 
27 (79.4) 
 
 
 
0.803 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 14 C: Other risk factors 
                                                                Cases           Control             p value 
Previous hospitalization: 
Yes
No
 
  11 (64.7) 
 
6 (35.3) 
 
    9 (26.5) 
 
25 (73.5) 
 
 
0.008 
Prior Antibiotic Intake: 
                                                             
                                                      Yes 
                                                      
                                                       No 
 
 
5 (29.4) 
 
12 (70.6) 
 
4 (11.8) 
 
30 (88.2) 
0.119 
Previous steroid/immunosuppressive: 
                                                      Yes 
                                                       No 
 
   11 (64.7) 
    6 (35.3) 
 
    18 (52.9) 
    16 (47.1) 
 
       0.42 
Infection at admission: 
                                                                
                                                     Yes 
 
                                                      No 
 
     
  10 (58.8) 
 
7 (41.2) 
 
     
   7 (20.6) 
 
27 (79.4) 
 
        0.006 
Invasive procedure done: 
                                                             
                                                     Yes 
 
                                                       No 
 
 
15 (88.2) 
 
2 (11.8) 
 
 
10 (29.4) 
 
24 (70.6) 
0.000 
Duration of Hospital stay (Days) 
 
Median
IQR
 
 
21 
(13, 25) 
 
 
6 
(4,   9) 
 
 
 
       <0.001 
 
 
Mortality 
             2            0 
 
- 
 
 
 
 
 
 
 
 
Table 15: Multivariate logistic regression analysis 
                                                  Odds ratio                                   p value 
Duration of hospital stay 
(1.51) 
 
CI: 1.19-1.92 
0.001 
Previous hospitalization 
(5.09) 
 
CI:  1.46-17.83 
0.01 
Infection at admission 
(5.51) 
 
CI:  1.29-111.32 
0.029 
Invasive procedure 
(18) 
 
CI: 3.08-93.68 
0.0000 
 
 
 
 Multivariate logistic regression was done on the factors found associated 
with NI in univariate analysis; the odds ratio and p values are as shown in table 
15. Duration of hospital stay, previous hospitalization, infection at admission and 
invasive procedures were found to be associated with NI. 
 
MANAGEMENT OF PATIENTS WITH NI 
 One patient was treated with parenteral vancomycin for MRSA infection. 
Six patients were started on empirical oral linezolid therapy for suspected MRSA 
skin infection which was later changed to oral cloxacillin since the culture grew 
MSSA.  For patients with gram negative infection oral/ i.v ciprofloxacin/ 
gentamicin/ levofloxacin/ amikacin/ imipenem according to susceptibility pattern 
were used. Three patients needed to be on artificial ventilation for treatment of 
NI. 
 
 
 
OUTCOME IN PATIENTS WITH NI 
 
Two patients, one with underlying erythroderma and the other with 
paraneoplastic pemphigus (PNP), developed clinical sepsis. One had bacteremia 
with Enterococci. The overall mortality rate was 0.48% and mortality among 
patients with NI was 11.76%. 
 
VIRAL INFECTION 
 Two patients were clinically diagnosed to have eczema herpeticum while 
in the ward, Tzanck smear was positive in both and herpes culture was positive 
in one. Since IgM HSV could not be done these were not included as NI. 
 
OTHER INFECTIONS 
 One patient developed diarrhoea due to Vibrio cholerae (non 01non 139) 
probably due to an outside food source. 
 
 
 
 
 
 
 
 
 
MRSA SKIN INFECTION 
A total of ten patients; Male (n = 6), Female (n= 4) were detected to have 
MRSA infection during the study period based on pus culture reports. Seven 
MRSA were isolated in patients who had disease which required hospitalization 
elsewhere and three were community-acquired. Their age group was (mean 30.8 
± SD15.86 years), body surface involvement (mean 14.3 ± SD 13.37), previous 
hospitalization within one month (n = 5), prior antibiotic intake within two weeks 
(n = 7), prior oral steroid (n = 6), immunosuppressant (n = 6), diabetes (n = 2). 
The primary dermatological diseases of the patients with MRSA is as shown in 
table 16.  The skin lesions at presentations were turbid blisters (n = 4), pustules 
(n = 2), erosions (n = 2), leg ulcer (n = 1) and discharging sinus (n = 1). 
Table 16: Patients with MRSA disease profile 
Disease profile No of patient  
Pemphigus 3 
Chronic bullous dermatosis of childhood 2 
Furunculosis 1 
Hansen’s disease 
 2 
 
Allergic contact dermatitis 1 
 
Pyoderma gangrenosum 1 
Total 10 
 
 
 Outcome in patients with MRSA infection      
Two patients received vancomycin, and the rest oral/ intravenous linezolid. Drugs 
were given for a total of 14 days. All the patients improved well with resolution of 
the infection. 
DISCUSSION 
 
Nosocomial infections are those acquired in or associated with hospitals. 
They are also known as hospital-acquired infections or, health care-associated 
infections. NI are common, and may be serious or fatal.11 Health care-associated 
infections constitute a major challenge of modern medicine and are considered 
one of the most accurate indicators of the quality of patient care.8  The Study on 
the Efficacy of NI Control (SENIC) found that a NI develops in 5-6% of 
hospitalized patients.5 The overall infection rate (number of hospital-acquired 
infections per 1,000 patients discharged) was highest in large teaching hospitals 
and lowest in non-teaching hospitals.3  Nosocomial infection are an important 
focus of infection prevention in all countries, but in developing countries they are 
a major cause of preventable disease and death.14  
Patients in the dermatology ward, with large areas of their skin denuded, 
and therefore with severely compromised barrier and immune function of the 
skin, are susceptible to develop various infections including sepsis.7 There are 
only a few studies on the incidence of development of NI among dermatology 
inpatients and an attempt has been made to study the same in a tertiary care 
referral centre. During the study period, a total of 421 patients were admitted to 
the dermatology ward. The primary dermatological diagnoses for which these 
patients were admitted were psoriasis (16.86%), autoimmune bullous disorders 
(11.87%), and Hansen’s disease (10.21%). Co-morbid diseases were seen in 
62.7% of these patients. Of the 421 patients, 28.26% had been diagnosed to 
have an infection at admission. Almost 60% of these patients had an appropriate 
culture done and 62.03% of the isolates were gram positive organisms. Of the 
isolates, S.aureus was the commonest (40.5%), followed by beta haemolytic 
Streptococcus (17.72%) and E.coli (10.12%). 9/32 (28.13%) of the S.aureus 
isolates were MRSA.  
During the study period the 421 patients admitted to the dermatology ward 
were evaluated for incidence of NI. Of the 421 patients, 17 (4.05%) developed 
NI.  A similar study in dermatology patients by Dettenkofer M et al6 reported an 
incidence of 2.5%.  However, a study conducted in AIIMS, Delhi reported a high 
incidence of sepsis of 6.6% among dermatology inpatients.7 
During the study period the comparison of NI between the total hospital 
patients and the dermatology ward showed a higher incidence among 
dermatology patients. However the methodology used to detect NI in the total 
hospital was different since the patients were surveyed only once a week and 
only those who were febrile were evaluated and hence the incidence of 0.57/100 
discharges is probably an underestimation. Two previous studies on incidence of 
NI, from our institution in the past, showed an incidence of 9.7% in the general 
medical wards in 1993 and 50.8% in the ICU in 1999. This reveals that NIs are of 
importance in tertiary care centers and also among dermatology inpatients and 
surveillance will help to establish the rate of endemic NI. 
In our study, the age group of patients who developed NI ranged from 20 
to 70 years with a mean age of 42.06 years. Two patients were more than 60 
years of age. It has been shown that patients at extremes of age are more prone 
to develop NI and have increased mortality.20,41 The majority of patients with NI 
were males (64.7%).  Five were over weight (BMI>25). Age, gender, BMI or 
diabetes mellitus were not significantly associated with development of NI in our 
study. 
In our study, the commonest primary dermatological diagnosis of patients 
who developed NI was autoimmune-bullous disorders. Other studies have 
reported an increased incidence of sepsis in patients with autoimmune-bullous 
disorders.7 The median body surface area involvement (BSA) in patients with NI 
was 30% with ten patients having more than 30% involvement. It has been 
shown that extensive skin involvement is a significant factor in patients who 
develop infection, and they are at high risk of mortality.7,41 Two patients (2/421) 
developed eczema herpeticum, their underlying primary disease being 
pemphigus vulgaris and lepromatous Hansen’s disease with necrotizing ENL 
respectively. Since HSV IgM was not done, they were not included under NI. 
There is a report of nosocomial outbreak of eczema herpeticum in dermatology 
ward patients.71 Eighty two percent of our patients who developed NI had chronic 
disease.    The primary dermatological disease, the duration of illness and body 
surface area of involvement were not significant risk factors for NI in our study. 
                     In our study, we found that the patients who had infection at admission 
were more prone to develop NI while in the ward. These patients were on 
antibiotic treatment after admission to the ward. Acquisition and transmission of 
antibiotic resistant S.aureus in the hospital mainly concerns intermittent and 
persistent nasal carriers treated with antibiotics.42 Since the carrier status of our 
patients was not determined, the importance of this factor in the development of 
NI could not be determined. However this merits further study. An increased 
chance of colonization followed by clinical infection in dermatology and burns 
patients has been reported.69 Eleven patients were on systemic 
steroids/immunosuppressive medications and five patients were on antibiotics 
prior to hospitalization. Though prior antibiotic and immunosuppressive therapy 
are regarded as risk factors in the development of NI,7,11,34,37 this was not found 
to be significant in our study. Eleven of 17 patients had history of previous 
hospitalization. This was a significant factor associated with development of NI 
and has been consistently shown in various studies to promote the development 
of NI and MRSA.11,52 The median duration of hospital stay in our patients with NI 
was 21 days. This was a significant factor among patients with NI as compared 
to controls and various studies support the evidence that prolonged stay in 
hospital is a risk factor for development of NI.7,40 In our study, fifteen patients 
among the NI group underwent invasive procedures like skin/ lymph node/bone 
marrow biopsy and nine of them had peripheral intravenous cannulation. Two 
patients who underwent lymph node biopsy developed abscesses at the local 
site. Since patients with skin disease may have loss of integrity of skin, this 
paves the way for colonization with hospital flora and subsequent development of 
NI. Dettenkofer et al6 showed that 57% of all NIs documented were SSI.  In our 
study a total of 22 bacterial isolates were obtained at the time of development of 
NI from these 17 patients. Among the NI, gram positive organisms were the 
commonest pathogens isolated from the skin lesions, of which S.aureus 
constituted 73.7% (14/19).  Thirteen (92.85%) of these were MSSA and only one 
was MRSA. In contrast, 9/32 (28.13%) of the S.aureus isolates from infected 
lesions at admission were MRSA. Majority of the isolates causing NI in previous 
studies on dermatology inpatients was also S.aureus 62.5% in the study by 
Selwyn et al36 and 41.8% in the study by Sharma et al7. 
 E.coli which was isolated from blood culture was resistant to all first line 
antibiotics and was susceptible only to imipenem. The urinary isolate P. 
aeruginosa was resistant to all first and second line antibiotics and E.coli was 
susceptible only to imipenem. The hospital acquired gram negative bacilli 
showed resistance to the first line antibiotics as reported by Sharma VK et al7 in 
the study of sepsis on dermatology patients. 
 In this study, 2 of 421 patients who developed sepsis died, mortality being 
0.48%. A similar study from Delhi, India on sepsis reported 2% of mortality 
among dermatology inpatients.7 So it is important to study the risk factors 
associated with development of NI among dermatology inpatients, which could 
help in instituting preventive measures. 
 
CONCLUSIONS 
 
1. The incidence of NI in dermatology inpatient study group was 4.05 / 100 
discharges with an incidence rate of 6.24 infections /1000 hospital days. 
2. Autoimmune bullous diseases were the commonest dermatological 
diagnosis among patients who developed NI (7/17, 41%). 
3. The types of NI seen were skin infections in 13 patients, SSI in 2 patients, 
urinary tract and blood stream infection in 1 patient each. 
4. The commonest organism causing an NI in our study population was  
S. aureus (63.6%) and among these there was only one isolate of MRSA.                             
5. Gram negative organisms causing NI were 22.72% of the isolates, and 
pseudomonas, E.coli, and P.mirabilis were resistant to all first line 
antibiotics. 
6. Median time to onset of NI was 11 days (IQR 8.10, 13.90.) 
7. Nosocomial infection was significantly associated with the following 
factors.  
           (a) Previous hospitalization (OR5.09, 95% CI 1.46 – 17.83) p   
           value=0.01  
(b) Infection at admission (OR 5.51, 95% CI 1.29 – 111.32) p value=0.029  
(c) Invasive procedures (OR 18, 95% CI 3.08 – 93.68) p value=0.0000 
8. Median duration of hospital stay among patients with NI was 21 days (IQR 
13, 25) and was significantly associated with NI (OR1.51, 95% CI 1.19 – 
1.92) p value=0.001 
9. Overall mortality rate among the study population was 0.48%, and 
mortality among patients with NI was 11.76%. 
 
SUMMARY 
 
A prospective cohort study was done to determine the incidence, the risk 
factors, and pathogens responsible for development of NI in the dermatology 
ward of a tertiary care centre from 1st November 2006 to 15th September 2007.  
During the study period, a total of 421 patients were admitted to the 
dermatology ward. The common primary dermatological diagnoses for which 
these patients were admitted were psoriasis (16.86%), autoimmune-bullous 
disorders (11.87%), and Hansen’s disease (10.21%). Co morbid diseases were 
seen in 62.7% of these patients. Of the 421 patients, 119 (28.26%) had been 
diagnosed to have an infection at admission. Almost 60% of these patients had 
an appropriate culture done and 62.03% of the isolates were gram positive 
organisms. Of the isolates, S.aureus was the commonest (40.5%), followed by 
Streptococcus (17.72%) and E.coli (10.12%). 9/32 (28.13%) of the S.aureus 
isolates were MRSA.  
Of the 421 patients studied, 17 patients developed NI with an incidence of 
4.05%, and an incidence rate of 6.24 infections/1000 hospital days. Of 119 
patients who had infections at admission, 10 developed NI. The mean age of the 
patients was 42.06 years with a male preponderance (64.7%). The commonest 
primary underlying dermatological diagnosis in patients with NI was autoimmune 
bullous-disorders. The median time to onset of NI was 11 days (IQR, 8.1, 13.9). 
The types of NI seen were skin infections in 13 patients, SSI in 2 patients, urinary 
tract and blood stream infection in 1 patient each. Eleven of them had previous 
hospitalization and were on steroid/immunosuppressive treatment. Fifteen of 
them had invasive procedures done. The median duration of hospitalization for 
patients with NI was 21 days (IQR 13, 25). This was significantly associated with 
NI (OR 1.51, 95% CI 1.19-1.92). The commonest organism causing an NI in our 
study population was S. aureus (63.6%) and among these there was only one 
isolate of MRSA.  Gram negative organisms causing NI were 22.72% of the 
isolates, and pseudomonas, E.coli, and P.mirabilis were resistant to all first line 
antibiotics. Nosocomial infection was significantly associated with the following 
factors: Previous history of hospitalization (OR5.09, 95% CI 1.46 – 17.83); 
infection at admission (OR 5.51, 95% CI 1.29 – 111.32) and invasive procedures 
(OR 18, 95% CI 3.08 – 93.68). Two patients among 421 died due to sepsis. 
Overall mortality rate among the study population was 0.48%, and mortality 
among patients with NI was 11.76%. 
 
. 
 
 
 
 
 
 
 
LIMITATIONS 
 
 
1. Nasal carriage detection could not be done for patients who were admitted 
due to financial constraints. 
 
2. Serology for IgM antibodies for HSV was not done and so Kaposi’s 
varicelliform eruption could not be classified as NI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for 
nosocomial infections.In: Olmsted RN, ed: APPIC Infection Control and Applied  
Epidemiology: Principles and Practice. St. Louis: Mosby; 1996: pp. A-1—A-20. 
 
2. Damani NN, editor. Manual of infection Control Procedures. 2nd ed. London: 
Greenwich Medical Media Ltd; 2003. 
 
3. Haley RW, Schaberg DR, Crossley KB, Von Allmen SD, Mc-Gowan JE Jr. 
Extra charges and prolongation of stay attributable to nosocomial infections: a 
prospective interhospital comparison. Am J Med 1981; 70: 51-8 
 
4. Bergogne-Berezin E. Current Guidelines for the Treatment and Prevention of 
Nosocomial Infections. Drugs 1999; 58:51-67 
 
5. Nosocomial Infection Surveillance  MMWR ; 1986 /35(SS-1);17-29. 
 
6. Dettenkofer M, Wilson C, Ebner W, Norgauer J, Ruden H, Daschner FD. 
Surveillance of nosocomial infections in dermatology patients in a German 
university hospital. Br J  Dermatol 2003;149: 620-623.  
 
7. Sharma VK, Asati DP, Khandpur S, Khilnani GC, Kapil A. Study of sepsis                    
in dermatology ward: A preliminary report. Indian J Dermatol Venereol Leprol 
2007; 73: 367.  
 
8. Sax H, Pittet D, Swiss-NOSO Network. Interhospital  Differences in 
Nosocomial Infection Rates. Arch Intern Med 2002; 162: 2437-42. 
 
9. Weber DJ, Rutala AW. Environmental Issues and Nosocomial Infections In: 
Wenzel.RP editor. Prevention and Control of Nosocomial Infections. 3rd edition. 
Baltimore. Williams & Wilkins publishers; 1997: 491-514. 
 
10.Sinkowitz-Cochran RL, Jarvis WR. Epidemiology and prevention of 
nosocomial Infection. In: Block SS editor. Disinfection, Sterilization and 
Preservation. 5th ed. Baltimore: Lippincott  Williams and Wilkins publishers; 2001. 
 
11. Breathnach SA. Nosocomial infections.  Medicine 2005; 33(3): 22-6. 
 
 12. Perl TM. Surveillance, Reporting, and the Use of Computers.In: Wenzel.RP 
editor. Prevention and Control of Nosocomial Infections. 3rd edition. Baltimore. 
Williams & Wilkins publishers; 1997: 127-61. 
 
13. Weinstein RA. Controlling antimicrobial resistance in hospitals : Infection 
control and use of antibiotics. Emerg Infect Dis 2001; 7: 188-92. 
14. Ponce-de-Leon S. The needs of developing countries and the resources 
required. J Hosp Infect 1991, 18 (Supplement): 376– 81. 
 
15. Laforce FM. The Control of Infections in Hospitals. In: Wenzel.RP editor. 
Prevention and Control of Nosocomial Infections. 3rd edition. Baltimore. Williams 
& Wilkins publishers; 1997:3-17. 
 
16. Mayon-White RT et al. An international survey of the prevalence of hospital 
acquired infection. J Hosp Infect 1988; 11 (Supplement A):43–8 
 
17. Mehta A, Rosenthal DV, Mehta Y, Chakravarthy M, Todi KS, Sen N et al, 
Device-associated nosocomial infection rates in intensive care units of seven 
Indian cities. Findings of the International Nosocomial Infection Control 
Consortium (INICC). Journal of Hospital Infection 2007; 67:168-74.  
 
18. Cherian R. Epidemiology of Nosocomial Infection in Medical Intensive Care 
Unit. MGR University; 1999. 
 
19. Inan D, Saba R, Gunseren F, Ongut G, Turhan O, Yalcin NA, Mamikoglu L. 
Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC 
Infectious Diseases 2005; 5.5: 1-6. 
 
20. Lakshmi SK, Jayashree M, Singhi S, Ray P. Study of Nosocomial Primary 
Bloodstream Infections in a Pediatric Intensive Care Unit. Journal of Tropical 
Pediatrics 2006; 6: 1-6. 
 
21. Khilnani P, Sarma D, Singh R, Uttam R, Rajdev S, Makkar A et al,  
Demographic profile and outcome analysis of a tertiary level pediatric intensive 
care unit . Indian Journal of Pediatrics. 2004; 71:587-91. 
 
22. Effird MM, Rojas MA, Lozano JM, Bose CL, Rojas MX, Rondon MA, et al. 
Epidemiology of nosocomial infection in selected neonatal intensive care units in 
Columbia, South America. J Perinatology 2005; 25:531-6. 
 
23. Malik A, Hasani ES, Khan MH, Ahmad JA. Nosocomial Infections in 
Newborn. Indian Pediatrics 2001; 38: 68-71. 
 
24. Zachariah A . Nosocomial Infection in Medical ward. MGR University;1993. 
 
25. Abdel-Fattah MM. Surveillance of nosocomial infections at a Saudi Arabian 
military hospital for a one-year period. GMS Ger Med Sci 2005; 3:1-11. 
 
26. Zhang Y. A two-year prospective survey on nosocomial infections. Zhonghua 
Yi Xue Za Zhi 1991; 71: 253-6. 
 
27. Wu AH, Wen XM, Ren N, Xu XH. Incidence and pathogens of nosocomial 
bacteremia  in China. Zhonghua Yi Xue Za Zhi 2003; 83: 395-8. 
 
28. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, 
Cardo DM. Estimating health care associated infections and deaths in US 
hospitals,2002. Public health reports, March-April 2007(cited 2007 
Dec8)Availablefrom 
:http://www.cdc.gov/ncidod/dhqp/pdf/hicpac/infections_deaths.pdf 
 
29. Vincent LJ, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH 
et al. The prevalence of Nosocomial Infection in Intensive Care Units in Europe  
(EPIC) study.  JAMA  1995; 274: 639-44 
 
30. Pittet D, Widmer A, Francioli P, Ruef C, Harbarth S. Prevalence and risk 
factors for nosocomial infections in four university hospitals in Switzerland. Infect 
Control Hosp Epidemiol 1999; 20:37-42. 
31. Ortona L, Federico G,  Fantoni M, Ardito F, Branca G, Caponera S. A study 
on the incidence of nosocomial infections in a large University hospital. European 
Journal of Epidemiology 1985; 1:94-9. 
32. Lizioli A,  Privitera G, Alliata E, Antonietta Banfi ME,  Boselli L, Panceri LM et 
al. Prevalence of nosocomial infections in Italy: result from the Lombardy survey 
in 2000.  Journal of hospital infection 2003; 54: 141-8. 
33.  Kim MJ, Jeoung SJ, Kim MK, Oh SH, Yoon WS, Chang SH, Lee S, Song HJ. 
Multicentre surveillance study for nosocomial infections in major hospitals in 
Korea.  American Journal of Infection Control  2000; 28: 454-8. 
34.  Wahie S, Lawrence CM.  Wound Complications Following Diagnostic Skin 
Biopsies in Dermatology Inpatients. Arch Dermatol  2007; 143 (10):1267-71. 
35. Wertheim HFL, Vos CM, Ott A, Belkum VA, Voss A, Kluytmans WJAJ et al. 
Risk and outcome of nosocomial Staphlococcus aureus bacteraemia in nasal 
carriers versus non-carriers. Lancet 2004; 364: 703-4. 
 
36. Selwyn S. Bacterial Infection in a skin department. Br J Dermatol  1962; 7: 
26-8. 
 
37. Colsky SA, Kirsner SR, Kedrel AF. Analysis of antibiotic susceptibilities of 
skin wound flora in hospitalized dermatology patients. Arch Dermatol 1998; 134: 
1006-9. 
 
38. Klevens RM, Morrison AM, Nadle J, Gershman K, Ray S, Harrison HE et al. 
Invasive Methicillin-Resistant Staphylococcus aureus infections in the United 
States. JAMA 2007; 298(15): 1763-71. 
 
39. Oie S, Yanagi C, Matsui H, Nishida T, Tomita M, Kamiya A. Contamination of 
Environmental Surfaces by Staphylococcus aureus in a Dermatological Ward 
and Its Prevention Measures. Biol Pharm Bull  2005; 28(1):120-3. 
 
40. Siegel DJ, Rhinehart E, Jackson M, Chiarello L. The Healthcare Infection 
Control Practices Advisory Committee Management of Multidrug-Resistant 
Organisms in Healthcare Settings. (Cited 2007 Dec10): 1-74. Available 
from.http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf 
 
41. Nair SP, Moorthy KP, Yogiragan K. A study of mortality in dermatology. 
Indian J Dermatol Venereology Leprol  2005; 71:23-5. 
 
42. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a 
source of staphylococcus aureus bacteremia. N Engl J Med 2001; 344: 11-6. 
 
43. Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, 
Versalovic J, et al. Three year surveillance of community-acquired 
Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40: 1785-91. 
 
44. Cookson B. Is it time to stop searching for MRSA? Br Med J 1997; 314:664-
6.  
 
45. Khairlddin N, Bishop L, Lamagni LT, Sharland M, Duckworth G. Emergence 
of MRSA bacteraemia among children in England and Wales, 1990-2001. Arch  
Dis Child 2004; 89:378-9. 
 
46. Lin KS, Yang CK, Chen YW, Li CH. A survey of Staphylococcus aureus 
Nosocomial Infection among Hospitalized Patients in a Medical Centre. 
https://teb.cdc.gov.tw/upload/doc/17482_EVOL11NO12_185.pdf.accessed 
10:12:2007. 
 
47. Adwan K, Abu-Hasan N, Adwan G, Jarrar N, Abu-Shanab B, Abu-Zant A. 
Nosocomial infection caused by methicillin-resistant Staphylococcus aureus in 
Palestine. Microb Drug Resist  2005 ;11(1): 75-7. 
 
48. Shigeruko I, Yoshikazu N, Masako T, Masaru S. Frequency of Infection 
Caused by Staphylococcus Aureus and Staphylococcus Aureus and Its 
Antimicrobial Susceptibility in Dermatology Compared with Other Clinics.  
Nishinihon Journal of Dermatology 2002; 64: 344-50. 
 
49.  Klevens RM, Morrison AM, Nadle J, Gershman K, Ray S, Harrison HE et al. 
Invasive Methicillin-Resistant Staphylococcus aureus infections in the United 
States. JAMA 2007; 298(15): 1763-71. 
 
50. Patil R, Baveja S, Nataraj G, Khopkar U. Prevalence of methicillin-resistant 
Staphylococcus aureus in community-acquired primary pyoderma. Indian J 
Dermatol Venereol Leprol 2006; 72:126-8. 
 
51. Krishna BV, Patil AB, Chandrsekhar MR. Community-acquired MRSA 
infection in a south Indian city. Southeast Asian J Tropical Med Public Health 
2004; 35(2):371-4. 
 
52.  Mehta A, Rodrigues C, Kumar R, Rattan A, Sridhar H, Mattoo V et al. A pilot 
programme of MRSA surveillance in India. (MRSA Surveillance Study Group) J 
Postgrad Med 1996; 42:1-3. 
 
53. Mendiratta PL, Vidhani S, Mathur MD. A study on staphylococcus aureus 
strains submitted to a reference laboratory. Indian J Med Res 2001; 114:90-4 
 
54. Vidhani S, Mehndiratta PL, Mathur MD. Study of methicillin resistant 
S.aureus isolates from high risk patients. Indian J Medical Microbiology 2001;19: 
13-6. 
 
55. Rajaduraipandi R, Mani RR, Panneerselvam R, Mani M, Bhaskar M, 
Manikandan P. Prevalence and antimicrobial susceptibility pattern of methicillin 
resistant Staphylococcus aureus: a multicentre study. Indian J Med Microbiology 
2006; 24(1):34-8. 
56. Mulla S, Patel M, Shah L, Vaghela G. Study of antibiotic sensitivity pattern of 
methicillin-resistant Staphylococcus aureus. Indian J Crit Care Med. 2007; 11: 
99-101. 
57. Balslev U, Bremmelgaard A, Svejgaard E, Havstrevm J, Westh H. An 
outbreak of borderline oxacillin-resistant Staphylococcus aureus (BORSA) in a 
dermatological unit.  Microb Drug Resist  2005 ;11(1):78-81. 
58. Helali NE, Carbonne A, Naas T, Kerneis S, Fresco O, Giovangrandi Y et al. 
Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: 
epidemiological investigation and control. Journal of Hospital Infection 2005; 
61:130-8. 
59. Sachdev D, Amladi S, Natraj G, Baveja S, Kkarkar V, Khopkar U et al. An 
ourbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection in 
dermatology indoor patients. Indian J Dermatol Venereol Leprol  2003; 69: 377-
80. 
60. Davis AK, Justin J. Stewart, Crouch KH,  Florez EC, Hospenthal RD. MRSA 
nasal Colonization at Hospital  Admission and Its Effect on Subsequent MRSA 
infection. Clin Infec Dis 2004; 39:776-82. 
 
61. Ayliffe J.A.G, Green W, Livingston R, Lowbury L.J.E. Antibiotic– resistant 
Staphylococcus aureus in dermatology and burn wards. J Clin Path 1977; 30:40-
4. 
62. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, 
Tenover FC et al. Prevalence of Staphylococcus aureus nasal colonization in the 
United States, 2001-2002. J Infect Dis 2006; 193(2):172-9. 
 
63.  Saxena S, Singh K, Talwar V. Methicillin – Resistant Staphylococcus aureus 
Prevalence in Community in the East Delhi Area. Jpn J Infect Dis 2003; 56:54-6 
 
64. Majumder D, Borodoloi JN Sarma, Phukan AC, Mahanta J. Antimicribial 
susceptibility pattern among MRSA isolates in Assam. Indian J Med Microbiology 
2001; 19: 138-40. 
 
65.  von Eiff C, Proctor RA, Peters G. Coagulase negative staphylococci. 
Postgrad Med 2001;110(4): 63-4. 
 
66. Raja NS, Karunakaran R, Ngeow YF, Awang R. Community-acquired 
vancomycin-resistant Enterococcus faecium: a case report from Malaysia. J Med 
Microbiol 2005; 54:901-3. 
 
67. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach 
DJ,et al. A nationwide, multicenter, case-control study comparing risk factors, 
treatment, and outcome for vancomycin-resistant and -susceptible enterococcal 
bacteremia. Diagn Microbiol Infect Dis 2000; 36:145-58. 
68. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. 
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clin Infect 
Dis 2005; 41: 848-54. 
 
69.  Mehta M, Dutta P, Gupta V. Bacterial isolates from burn wound infections 
and their antibiograms: A eight year study. Indian J Plast Surg 2007; 40: 25-8. 
 
70. Mohanty S, Kapil A, Dhawan B, Das BK. Bacteriological and antimicrobial 
susceptibility profile of soft tissue infections from Northern India. Indian J Med 
Sci. 2004;58:10-15. 
 
 
71. Rao RRG, Chalam VK, Prasad PG, Saranathan M, Kumar YKH. Mini 
outbreak of Kaposi’s varicelliform eruption in skin ward: A study of five cases. 
Indian J Dermatol Venereol Leprol 2007; 73: 33-5.  
 
72. Adler SP. Herpes Simplex. In: Mayhall CG editor. Hospital Epidemiology and 
Infection Control. Baltimore Williams and Wilkins; 1996; 437-40. 
 
73. Perl TM, Haugen TH, Pfaller MA. Transmission of herpes simplex virus type I 
infection in and intensive care unit. Ann Intern Med. 1992; 117: 584-6. 
 
74.  Adams G, Stover BH, Keenlyside RA. Nosocomial herpetic infections in a 
pediatric intensive care unit. Am J Epidemiol  1981; 113: 126-32. 
 
 75. Sakaoka H, Saheki Y, Uzuki K, Nakakita T, Saito H, Sekine K et al.Two out 
breaks of Herpes Simplex Virus Type 1 Nosocomial Infection among Newborns. 
Journal of Clinical Microbiology1986; 24: 36-40. 
 
76. Fridkin KS, Jarvis RW. Epidemiology of Nosocomial Fungal Infections. 
Clinical Microbiology Reviews  1996; 9: 499-11. 
 
77.  Beck-Sague, C. M., W. R. Jarvis, and the National Nosocomial Infections 
Surveillance System. Secular trends in the epidemiology of nosocomial 
fungal infections in the United States, 1980–1990. J  Infect  Dis 1993.167: 
1247–51. 
 
78. Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of Candidemia 
in a Tertiary Care Centre of North India: 5 year study. Infection 2007;35: 256-9 
 
79. Sahni V, Agarwal KS, Singh PN, Anuradha S, Sikdar S, Wadhwa A, Kaur R. 
Candidemia — An Under-recognized Nosocomial Infection in Indian Hospitals 
JAPI  2005 ;53 : 607-11. 
 
 
 
 
80. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S, Solbiati M. 
Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care 
Hospital. European Journal of Clinical Microbiology & Infectious Diseases 2004; 
19: 602-7. 
 
81. Archer-Dubon C, Icaza-Chivez ME, Reyes E, Baez-Martinez R, Ponce de 
Leon S.AN epidemic outbreak of malassezia folliculitis in three adult patients in 
an intensive care unit: a previously unrecognized nosocomial infection. Int J 
Dermatol 1999; 38: 453-56. 
  
82. Sibbald GR, Williamson D, Orsted LH, Campbell K, Keast D, Krasner D et al. 
Preparing the Wound Bed-Debridement, Bacterial Balance, and Moisture 
Balance. Ostomy/Wound Management 2000; 46:14-35. 
 
83. Myer’s and Koshi’s manual of diagnostic procedures in medical microbiology 
and immunology/ serology). Revised Edit. Pondicherry: All India Press; 2001. 
 
84. Performance Standards for Antimicrobial Susceptibility Testing. M100:S17 
(M2; A19 & M7; A7) No.1. Pennsylvania USA: Clinical and Laboratory Standards 
Institute; 2007; 27 (Suppl 7). 
 
 
 
 
Annexure I 
 
 
 
INFORMED CONSENT DOCUMENT 
 
 
 It has been explained to me that the study involves my examination, the 
necessity of investigations as well as need for regular follow up. I also 
understand that the information I divulge is confidential and shall be used for 
study purposes only. Thereafter I give my informed consent for the same. 
 
 
 
 
Date:             Signature of the patient/guardian 
CMCH, Vellore. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure II 
 
Proforma: 
 
DERMATOLOGY WARD NOSOCOMIAL INFECTION (NI) SURVEILLANCE 
 
Name                          Hospital No.                                      Age/Sex  
 
Occupation:                    Ward:                                 Ht:                   Wt: 
                                                                                                        BMI: 
DOA:                               DOD: 
 
No. days hospital stay: 
Duration of illness: 
    Dermatological:                                                     Skin lesions: 1. Primary 
Non dermatological:                                                                   2. Secondary 
 
                                                                      Body surface Area Involvement: 
 
Temperature at admission :                                             Duration of  fever 
Associated symptoms: 
 
Previous hospitalization:    Yes/ No 
Treatment:  Previous Medications:               Yes/ No 
 
 If  Yes-date/details:  Antibiotics: 
 
Steroids( Topical/Oral) 
 
Immunosuppressive: 
 
Others: 
 
 
 
 
  
 
 
 
 
 
 
Diagnosis: Dermatological: 
 
          Non Dermatological: 
  Date           PR       RR     BP     Temp                       Skin lesions               Systemic exam 
1. 
2. 
3. 
 
 
 
Initial Microbiology:   
 
     Date                        Specimen                              Gram stain           Culture/Sensitivity 
1. 
2. 
3. 
Treatment: 
Antibiotic                     date started                   last date                     reason for stopping 
 
1. 
 
2. 
 
3. 
 
Invasive procedure done:          Yes/ No 
 
 
If Yes- Procedure done:             
 
 
 
 
 
        Date                                               procedure                                                     result 
 
1. 
2. 
3.                   
                 
 
Suspicion of  NI date: 
Reason for Diagnosis of NI 
1. 
2. 
3. 
 
Microbiology  suspected NI: 
 
        Date                   specimen                           Gram stain                                     C/S                                                                        
 
1. 
2. 
3. 
 
Antibiotic for NI             date started                   last date              reason for stopping 
 
1. 
 
2. 
 
3. 
 
 
 
 
Final outcome:  
 
 Condition at discharge: Improved/Statisquo: 
 
 
 Drugs at discharge: 
 
 
 
  Follow up at 1 week after discharge:  
Annexure III 
CDC Definition of Nosocomial Infections 
INFECTION SITE: Skin 
CODE: SST-SKIN 
DEFINITION: Skin infections must meet at least one of the following criteria: 
Criterion 1: Patient has purulent drainage, pustules, vesicles,or boils. 
Criterion 2: Patient has at least two of the following signs or symptoms with no other recognized 
cause: painor tenderness, localized swelling, redness, or heat 
and 
at least one of the following: 
a. Organisms cultured from aspirate or drainagefrom affected site; if organisms are normal skin 
flora (e.g., coagulase negative staphylococci, micrococci, diphtheroids) they must be a pure 
culture 
b. Organisms cultured from blood 
c. Positive antigen test performed on infected tissue or blood (e.g., herpes simplex, varicella 
zoster, H. influenzae, N. meningitidis) 
d. Multinucleated giant cells seen on microscopic examination of affected tissue 
e. Diagnostic single antibody titer (IgM) or fourfold increase in paired sera (IgG) for pathogen  
COMMENT: 
_ Nosocomial skin infections may be the result of exposure to a variety of procedures performed 
in the hospital. Superficial incisional infections after surgery are identified separately as SSI-SKIN 
unless the operative procedure is a CBGB. If the chest incision site after a CBGB becomes 
infected, the specific site is denoted SKNC; if the donor site becomes infected, the specific site is 
denoted SKNL. Other skin infections associated with important exposures are identified with their 
own sites and are listed in the section on reporting instructions. 
REPORTING INSTRUCTIONS: 
_ Report omphalitis in infants as UMB. 
_ Report infections of the circumcision site in newborns as 
CIRC. 
_ Report pustules in infants as PUST. 
_ Report infected decubitus ulcers as DECU. 
_ Report infected burns as BURN. 
_ Report breast abscesses or mastitis as BRST. 
INFECTION SITE: Soft tissue (necrotizing fascitis, infectious 
gangrene, necrotizing cellulitis, infectious myositis, lymphadenitis, 
or lymphangitis) 
CODE: SST-ST 
DEFINITION: Soft tissue infections must meet at least one of the following criteria: 
Criterion 1: Patient has organisms cultured from tissue or drainage from affected site. 
Criterion 2: Patient has purulent drainage at affected site. 
Criterion 3: Patient has an abscess or other evidence of infecSection 
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surgical operation or histopathologic examination. 
Criterion 4: Patient has at least two of the following signs of symptoms at the affected site with no 
other recognized ca use: localized pain or tenderness, redness, swelling, or heat  
and 
at least one of the following: 
a. Organisms cultured from blood 
b. Positive antigen test performed on blood or urine (e.g., H. influenzae, S. pneumoniae, N. 
meningitidis, group B Streptococcus, Candida sp.) 
c. Diagnostic single antibody titer (IgM) or fourfold increase in paired sera (IgG) for pathogen 
REPORTING INSTRUCTIONS: 
_ Report surgical site infections that involve both the skin and deep soft tissue (at or beneath the 
fascial or muscle layer) as SSI-ST (soft tissue) unless the operative procedure is a CBGB. 
For CBGB, if skin and deep soft tissue at the chest incision site become infected, the specific site 
is STC and if skin and deep soft tissue at the donor site become infected, the specific site is STL. 
_ Report infected decubitus ulcers as DECU. 
_ Report infection of deep pelvic tissues as OREP. 
 
INFECTION SITE: Decubitus ulcer, including both superficial and deep infections 
CODE: SST-DECU 
DEFINITION: Decubitus ulcer infections must meet the following criterion: 
Patient has at least two of the following signs or symptoms with no other recognized cause: 
redness, tenderness, or swelling of decubitus wound edges 
And  
at least one of the following: 
a. Organisms cultured from properly collected fluid or tissue (see later) 
b. Organisms cultured from blood 
COMMENTS: 
_ Purulent drainage alone is not sufficient evidence of an infection.  
_ Organisms cultured from the surface of a decubitus ulcer are 
not sufficient evidence that the ulcer is infected. A properly collected specimen from a decubitus 
ulcer involves needle aspiration of fluid or biopsy of tissue from the ulcer margin. 
 
INFECTION SITE: Surgical site infection (deep incisional)  
CODE: SSI-[ST (soft tissue)] except following the NNIS operative procedure, CBGB. For CBGB 
only, if infection is at chest site, use STC (soft tissue-chest) or if at leg (donor) site, use STL (soft 
tissue-leg) 
DEFINITION: A deep incisional SSI must meet the following criteria: 
Infection occurs within 30 days after the operative procedure if no implantb is left in place or 
within 1 year if implant is in place and the infection appears to be related to the operative 
procedure 
 and 
involves deep soft tissues (e.g., fascial and muscle layers) of the incision 
and 
patient has at least one of the following: 
a. Purulent drainage from the deep incision but not from the organ/space component of the 
surgical site 
b. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the 
patient has at least one of the following signs or symptoms: fever (_38_C) or localized pain or 
tenderness, unless incision is culture-negative c. An abscess or other evidence of infection 
involving the deep incision is found on direct b A nonhuman-derived implantable foreign body 
(e.g., prosthetic heart valve, nonhuman vascular graft, mechanical heart, or hip prosthesis) that is 
permanently placed in a patient during surgery.Chapter 94: Surveillance of Nosocomial Infections 
1675 examination, during reoperation, or by histopathologic or radiologic examination 
d. Diagnosis of a deep incisional SSI by a surgeon or attending physician 
REPORTING INSTRUCTIONS: 
_ Classify infection that involves both superficial and deep incision sites as deep incisional SSI._ 
Report culture specimen from deep incisions as ID. 
INFECTION SITE: Burn 
CODE: SST-BURN 
DEFINITION: Burn infections must meet one of the following criteria: 
Criterion 1: Patient has a change in burn wound appearance or character, such as rapid eschar 
separation; dark brown, black, or violaceous discoloration of the 
char; or edema at wound margin and histologic examination of burn biopsy shows invasion of 
organisms into adjacent viable tissue. 
Criterion 2: Patient has a change in burn wound appearance or character, such as rapid eschar 
separation; dark brown, black,  or violaceous discoloration of the 
eschar; or edema at wound margin and at least one of the following: 
a. Organisms cultured from blood in the absence of other identifiable infection 
b. Isolation of herpes simplex virus, histologic identification of inclusions by light or electron 
microscopy or visualization of viral particles by electron microscopy in biopsies or lesion 
scrapings 
Criterion 3: Patient with a burn has at least two of the following signs or symptoms with no other 
recognized cause: fever (_38_C) or hypothermia (_36_C), hypotension, oliguria (_20 cm3/hr), 
hyperglycemia at previously tolerated level of dietary carbohydrate, or mental confusion 
and 
at least one of the following: 
a. Histologic examination of burn biopsy shows invasion of organisms into adjacent viable tissue 
b. Organisms cultured from blood  
c. Isolation of herpes simplex virus, histologic I dentification of inclusions by light or electron 
microscopy, or visualization of viral particles electron microscopy in biopsies or lesion scrapings 
COMMENTS: 
_ Purulence alone at the burn wound site is not adequate for the diagnosis of burn infection; such 
purulence may reflect incomplete wound care.  
_ Fever alone in a burn patient is not adequate for the diagnosis  of a burn infection because 
fever may be the result of tissue trauma or the patient may have an infection at another site. 
_ Surgeons in Regional Burn Centers who take care of burn patients exclusively, may require 
Criterion 1 for diagnosis burn infection. 
_ Hospitals with Regional Burn Centers may further divide burn infections into the following: burn 
wound site, burn graft site, burn donor site, burn donor site-cadaver; the NNIS system, however, 
will code all of these as BURN. 
INFECTION SITE: Clinical sepsis 
CODE: BSI-CSEP 
DEFINITION: Clinical sepsis must meet at least one of the following criteria: 
Criterion 1: Patient has at least one of the following clinical signs or symptoms with no other 
recognized cause: 
fever (_38_C), hypotension (systolic pressure _90 mm Hg), or oliguria (_20 cm3/hr) 
and 
blood culture not done or no organisms or antigen detected in blood 
and 
no apparent infection at another site  
and 
physician institutes treatment for sepsis.  
Criterion 2: Patient _1 year of age has at least one of the following clinical signs or symptoms with 
no other recognized cause: fever (_38_C), hypothermia (_37_C), apnea, or bradycardia 
and 
blood culture not done or no organisms or antigen detected in blood 
and 
no apparent infection at another site 
and 
physician institutes treatment for sepsis. 
REPORTING INSTRUCTION: 
_ Report culture-positive infections of the bloodstream as BSILCBI. 
 
INFECTION SITE: Symptomatic urinary tract infection  
CODE: UTI-SUTI 
DEFINITION: A symptomatic urinary tract infection must meet at least one of the following 
criteria: 
Criterion 1: Patient has at least one of the following signs or symptoms with no other recognized 
cause: fever (_38_C), urgency, frequency, dysuria, or suprapubic tenderness 
and 
patient has a positive urine culture, that is, _105 microorganisms per cm3 of urine with no more 
than two species of microorganisms. 
Criterion 2: Patient has at least two of the following signs or Chapter 94: Surveillance of 
Nosocomial Infections 1673 symptoms with no other recognized cause: fever (_38_C), urgency, 
frequency, dysuria, or suprapubic tenderness 
and 
at least one of the following:  
a. Positive dipstick for leukocyte esterase and/or nitrate 
b. Pyuria (urine specimen with _10 WBC/mm3 or_3 WBC/high power field of unspun urine) 
c. Organisms seen on Gram stain of unspun urine  
d. At least two urine cultures with repeated isolation of the same uropathogen (gram-negative 
bacteria or S. saprophyticus) with _102 colonies/ mL in nonvoided specimens 
e. _105 colonies/mL of a single uropathogen (gram-negative bacteria or S. saprophyticus) in a 
patient being treated with an effective antimicrobial agent for a urinary tract infection 
f. Physician diagnosis of a urinary tract infection 
g. Physician institutes appropriate therapy for a urinary tract infection  
Criterion 3: Patient _1 year of age has at least one of the following signs or symptoms with no 
other recognized cause: fever (_38_C), hypothermia (_37_C), apnea, bradycardia, dysuria, 
lethargy, or vomiting  
and 
patient has a positive urine culture, that is, _105 microorganisms per cm3 of urine with no more 
than two species of microorganisms. 
Criterion 4: Patient _1 year of age has at least one of the following signs or symptoms with no 
other recognized  
cause: fever (_38_C), hypothermia (_37_C), apnea, bradycardia, dysuria, lethargy, or vomiting 
and 
at least one of the following: 
a. Positive dipstick for leukocyte esterase and/or nitrate 
b. Pyuria (urine specimen with _10 WBC/mm3 or_3 WBC/high power field of unspun urine) 
c. Organisms seen on Gram stain of unspun urine 
d. At least two urine cultures with repeated isolation of the same uropathogen (gram-negative 
bacteria or S. saprophyticus) with _102 colonies/ mL in nonvoided specimens 
e. _105 colonies/mL of a single uropathogen (gram-negative bacteria or S. saprophyticus) in a 
patient being treated with an effective antimicrobial agent for a urinary tract infection 
f. Physician diagnosis of a urinary tract infection 
g. Physician institutes appropriate therapy for a urinary tract infection 
COMMENTS: 
_ A positive culture of a urinary catheter tip is not an acceptable laboratory test to diagnose a 
urinary tract infection. 
_ Urine cultures must be obtained using appropriate technique, such as clean catch collection or 
catheterization. 
_ In infants, a urine culture should be obtained by bladder catheterization or suprapubic 
aspiration; a positive urine culture from a bag specimen is unreliable and should be confirmed by 
a specimen aseptically obtained by catheterization 
or suprapubic aspiration. 
INFECTION SITE: Asymptomatic bacteriuria 
CODE: UTI-ASB 
DEFINITION: An asymptomatic bacteriuria must meet at least one of the following criteria: 
Criterion 1: Patient has had an indwelling urinary catheter within 7 days before the culture 
and 
patient has a positive urine culture, that is, _105 microorganisms per cm3 of urine with no more 
than two species of microorganisms 
and 
patient has no fever (_38_C), urgency, frequency, dysuria, or suprapubic tenderness. 
Criterion 2: Patient has not had an indwelling urinary catheter within 7 days before the first 
positive culture 
and 
patient has had at least two positive urine cultures, that is, _105 microorganisms per cm3 of urine  
with repeated isolation of the same microorganism and no more than two species of 
microorganisms  
and 
patient has no fever (_38_C), urgency, frequency, dysuria, or suprapubic tenderness. 
COMMENTS: 
_ A positive culture of a urinary catheter tip is not an acceptable laboratory test to diagnose 
bacteriuria. 
_ Urine cultures must be obtained using appropriate technique, such as clean catch collection or 
catheterization. 
APPENDIX A-2. PNEUMONIA ALGORITHMS 
Major Site: Pneumonia (PNEU) 
Site-Specific Algorithms for Clinically Defined Pneumonia (PNU1) 
Radiology Signs/symptoms/laboratory Code 
Two or more serial chest radiographs with at least one 
of the following1,2: New or progressive 
and persistent infiltrate  
Consolidation 
Cavitation 
Pneumatoceles, in infants _1 year old 
NOTE: In patients without 
underlying pulmonary or 
cardiac disease (e.g., respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary 
edema, or chronic obstructive pulmonary disease),  
one definitive chest radiograph is acceptable1. 
PNU1 
FOR ANY PATIENT, at least one of the following: 
• Fever (_38°C or _100.4°F) with no other recognized cause 
• Leukopenia (_4,000 WBC/mm3) or leukocytosis (_12,000 WBC/mm3) 
• For adults _70 years old, altered mental status with no other recognized cause 
and 
At least two of the following: 
• New onset of purulent sputum3, or change in character of sputum4, or increased respiratory 
secretions, or increased suctioning requirements 
• New onset or worsening cough, or dyspnea, or tachypnea5 
• Rales6 or bronchial breath sounds 
• Worsening gas exchange (e.g., O2 desaturations [e.g., PaO2/FiO2 _240]7, increased oxygen 
requirements, or increased ventilation demand) 
ALTERNATE CRITERIA FOR INFANT _1 YEAR OLD: 
Worsening gas exchange (e.g., O2 desaturations, increased oxygen requirements, or increased 
ventilator demand) 
and 
at least three of the following: 
• Temperature instability with no other recognized cause 
• Leukopenia (_4,000 WBC/mm3) 
or leukocytosis (_15,000 WBC/mm3) and left shift (_10% band forms) 
• New onset of purulent sputum3, or change in character of sputum4, or increased respiratory 
secretions, or increased suctioning requirements 
• Apnea, tachypnea5, nasal flaring with retraction of chest wall, or grunting 
• Wheezing, rales6, or rhonchi 
• Cough 
• Bradycardia (_100 beats/min) or tachycardia (_170 beats/min) 
ALTERNATE CRITERIA FOR CHILD _1 OR _12 YEARS OLD, at least three of the following: 
• Fever (_38.4°C or _101.1°F) or hypothermia (_37°C or _97.7°F) with no other recognized 
cause 
• Leukopenia (_4,000 WBC/mm3) or leukocytosis (_15,000 WBC/mm3) 
• New onset of purulent sputum3, or change in character of sputum4, or increased respiratory 
secretions, or increased suctioning requirements 
• New onset or worsening cough or dyspnea, apnea, or tachypnea5 
• Rales6 or bronchial breath sounds 
• Worsening gas exchange (e.g., O2 desaturations [e.g., pulse oximetry _94%], increased oxygen 
requirements, or increased ventilation demand). 
 
Annexure IV              GLOSSARY FOR MASTER SHEET 
For the columns, code is indicated below the abbrevation 
C1 S.No   
C2 Hospt.No   
C3 Age (Yrs)   
C4 Sex   
C5 BMI   
C6 DOA   
C7 DOD   
C8 Dur illness Derm   
C9 
Diagnosis 
Dermatological 
1= Psoriasis; 2= Autoimmune-bullous disorder; 3= Other 
dermatoses; 4= Hansen’s disease; 5= Allergic contact 
dermatitis; 6= Drug reactions; 7= Viral diseases; 8= 
Erythroderma; 9   = Atopic dermatitis; 10 = Urticaria; 11 = 
Chronic leg ulcer; 12 = Vasculitis; 13 = Vitiligo; 14 = Cellulitis 
15 = Panniculitis; 16 = Skin malignancy; 17 = Connective 
tissue disorder  
C10 
Diagnosis Non 
Dermatological 
1 = Type II Diabetes Mellitus; 2 = Essential Hypertension; 3 
=Anemia (iron deficiency/ chronic disease); 4 = Dyslipidemia 
5 = Obesity; 6 = COPD*; 7 = Osteoarthritis;  
8 = Hypothyroidism; 9    = Tuberculosis; 10  = HIV infection; 11  
=Seizure disorder; 12  = Osteoporosis 
C11 BSA (%)   
C12 Previous Hoptalization  1= Yes; 2 = No 
C13 Previous Antibiotic 1= Yes; 2 = No 
C14 Previous Steroids  1A = Prednisolone; 1B = Dexamethasone; 1C = Injectable steroid ; 1D = Topical steroid 
C15 
Previous 
Immunosuppressives 
1A = Methotrexate ; 1B = Azoran; 1C = Mycept ; 1D = 
Cyclosporin ; 1E = Cyclophosphamide; 1F = DCP pulse 
1G = Retinoids (oral) 
C16 Initial Micro (Date)   
C17 
Specimen 1 = Pus ; 2 = Blood; 3 = Urine ;4 = Sputum;5 = Stool ;6 = 
Herpes culture;7 = Tissue culture;8 = Blister fluid;9 = Throat 
swab;10 = Tsank smear 
C18 
Culture sensitivity 1 = Coag. Neg Staph;2 = MSSA;3 = MRSA;4 = Enterococcus 
5 = Enterobacter;6 = Micrococcus;7 = Pseudomonas;8 = 
Klebsiella; 9 = Proteus;10= β streptococcus;11 = no growth 
12 = NFGNB;13 = Diptheria;14 = E.Coli;15 = Herepes growth 
present;16 = MNG;17 = Shigella;18 Citrobacter  
C19 
Treatment Antibiotic 1 = Cap. Cloxacillin;2 = Inj. Cloxacillin;3 = T.Linezolid 
4 = T. Ciprofloxacin;5 = Inj. Ciprofloxcin;6 = Inj. Gentamycin 
7 = Inj. Cefataxime;8 = Inj. Vancomycin;9 = Inj. Levofloxacin 
10 = T. Levofloxacin;11 = Inj.Cefipime;12 = Inj. Ceftazidime 
13 = T. Cefedroxil;14 = Cap. Amoxy;15 = Inj. Linezolid 
16 = T. Doxycyclin;17 = T. Acyclovir;18 = Cap. Cephalexin 
19 = T.Metronidazole;20 = Inj. Cefazolin;21 = T.Azithromycin 
22 = Inj.Amikacin;23 = T.Erythromycin;24 = T.Augmentin 
25 = T.Norfloxcin;26 = T.Septran;27 = Fucidin cream;          28 
= Muprocin cream 
C20 
Procedure 1 = skin biopsy; 2 = i.v line; 3 = lymph node biopsy; 4 = bone 
marrow biopsy; 5 = central line; 6 = FNAC; 7 = I&D; 8 = 
Lumbar puncture 
C21 Micro NI Date   
C22 
Specimen 1 = Pus; 2 = Blood; 3 = Urine; 4 = Sputum; 5 = Stool ; 6 = 
Herpes culture; 7 = Tissue culture; 8 = Blister fluid; 9 = Throat 
swab; 10 = Tsank smear 
C23 Gram Stain  1 = GPC; 2 = GNB; 3 = GPB 
C24 
C/S 1 = Coag. Neg Staph;2 = MSSA;3 = MRSA;4 = Enterococcus 
5 = Enterobacter;6 = Micrococcus;7 = Pseudomonas;8 = 
Klebsiella; 9 = Proteus;10= β streptococcus;11 = no growth 
12 = NFGNB;13 = Diptheria;14 = E.Coli;15 = Herepes growth 
present;16 = MNG;17 = Shigella;18 Citrobacter  
C25 
Antibiotic for NI 1 = Cap. Cloxacillin;2 = Inj. Cloxacillin;3 = T.Linezolid 
4 = T. Ciprofloxacin;5 = Inj. Ciprofloxcin;6 = Inj. Gentamycin 
7 = Inj. Cefataxime;8 = Inj. Vancomycin;9 = Inj. Levofloxacin 
10 = T. Levofloxacin;11 = Inj.Cefipime;12 = Inj. Ceftazidime 
13 = T. Cefedroxil;14 = Cap. Amoxy;15 = Inj. Linezolid 
16 = T. Doxycyclin;17 = T. Acyclovir;18 = Cap. Cephalexin 
19 = T.Metronidazole;20 = Inj. Cefazolin;21 = T.Azithromycin 
22 = Inj.Amikacin;23 = T.Erythromycin;24 = T.Augmentin 
25 = T.Norfloxcin;26 = T.Septran;27 = Fucidin cream;          28 
= Muprocin cream 
C26 Date start    
C27 Last Date   
C28 
Reason for Stopping 
antibiotic  
1 = Complete course; 2 = Empirical; 3 = Coag. Neg staph 
4 = Lesion not better; 5 = Angiodema; 6 = difficult i.v access 
7 = fever persisting; 8 = continued; 9 = change to oral 
10 = better 
C29 Condition at discharge 1 = improved; 2 = expired; 3 = statisquo  
C30 Follow up at 1 wk 1 = normal; 2 = new turbid vesicles; 3 = not better; 4 = not known 
